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ABSTRACT 
    Natural products from bacteria play an important role in disease control. In 
this thesis, we investigated the biosynthetic mechanism of vioprolides. 
Vioprolides are peptolides produced by the myxobacterium Cystobacter 
violaceus Cb vi35 with prominent cytotoxicity and anti-fungal activity. Here we 
elucidated the biosynthetic pathway of vioprolides and expressed the vio gene 
cluster successfully in heterologous hosts Myxococcous xanthus DK1622 
(ΔmchA), Burkholderia sp. DSM7029 and Pseudomonas putida KT2440. 
Vioprolides are initially synthesized as previoprolides which undergo post-
assembly deacylation and extracellular secretion. We identified an unusual C 
domain in the NRPS machinery that catalyzes glycerate esterification in the 
initiation of the assembly line, and validated this process by in vitro biochemical 
characterization. Furthermore, site-directed mutagenesis was carried out to 
generate various novel vioprolide derivatives. 
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ZUSAMMENFASSUNG 
Naturprodukte aus Bakterien spielen eine wichtige Rolle bei der 
Krankheitskontrolle. In dieser Arbeit untersuchten wir die Biosynthese von 
myxobakteriellen Wirkstoffen, den Vioproliden. Vioprolide sind Peptolide und 
werden vom Myxobakterium Cystobacter violaceus Cb vi35 mit prominenten 
Zytotoxizität und antifungaler Aktivität produziert. Hier erläutern wir den 
Biosyntheseweg der Vioprolide. Wir exprimierten das „vio“ Gencluster 
erfolgreich in folgenden heterologen Wirten: Myxococcous xanthus DK1622 
(ΔmchA), Burkholderia DSM 7029 und Pseudomonas putida KT2440. 
Vioprolide werden zunächst als Pre-vioprolide synthetisiert, die „Post-
Assembly“ einer Deacylierung und extrazellulärer Sekretion unterliegen.  Wir 
identifizierten eine ungewöhnliche C-Domäne, die eine Glyzerinveresterung zu 
Beginn der Biosynthesekette katalysiert und validierten diesen Prozess durch in 
vitro Studien für die biochemische Charakterisierung. Weiterhin wurde „Site-
directed“ Mutagenese durchgeführt, um verschiedene Derivative der Vioprolide 
zu erzeugen. 
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1. INTRODUCTION 
1.1 Natural products in drug discovery 
The use of natural products to treat human diseases dates back to the early 
recorded history [1]. They played and continue to play notable roles clinically. 
Natural products from bacteria, fungi cyanobacteria and plants exhibit diverse 
biological activities such as anti-infectives, cytotoxins, immunosuppressors and 
antidiabetics etc. [2–4] (Fig. 1.1). Among all of the drugs applied in disease 
treatment in the last several decades, more than 48% derive from natural 
products or derivatives thereof. Furthermore, half of the chemically synthesized 
drugs are based on natural product cores or their mimics [3]. From the 326 anti-
infective drugs approved from 1981 to 2014, around 50% of them are natural 
products-related (Fig. 1.2) [3]. More specially, around 60% of antibacterial 
agents derive from natural products, and most of them originate from microbes. 
Comparably, in 174 anticancer drugs in this 34 years period, only 13% are 
originally synthetic. 
 
Fig. 1.1 Selected clinically introduced natural products. The name, bioactivity 
and original producer is shown below the chemical structures. 
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Fig. 1.2 Approved drugs from 1981-2014 (modified from [3]). 
 
Antibiotics have played an important role to cure infectious diseases for more 
than 70 years. Alexander Fleming’s discovery of penicillin in 1928 opened the 
antibiotic age [5]. Afterwards the development of antibiotics ushered in its 
golden age. Many important antibiotics which we still use today, e.g. 
cephalosporins, chloramphenicol, erythromycin, kanamycin and oxytetracycline, 
were discovered at that time. However, since 1970s the number of newly 
discovered antibiotics began to decline. Meanwhile, more and more serious 
antibiotics resistance emerged [6] (Fig. 1.3). Today there are still millions of 
deaths in the world wide each year caused by the infection of bacterial, fungal, 
viral or parasitic pathogens. As the widespread misuse of antibiotics increased, 
accelerating resistance emerged and is now found wide spread in 
microorganisms [7]. The clinically most relevant ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) are 
of increasing importance for antimicrobial therapy in the foreseeable future [8–
11]. Besides of bacteria infection, infection of fungi Candidiasis is common in 
the world wide. Especially invasive Candida usually causes high morbidity and 
mortality rates [12, 13]. However, only three classes of antifungal agents, the 
azoles, the echinocandins and the polyenes, are used clinically. Resistance to the 
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azoles is becoming common and resistance to the newest antifungal drug 
echinocandins is also emerging in Candidiasis [8]. In contrast to the significant 
increase of antimicrobial resistance (AMR) in the post-antibiotic-era, 
nonetheless, pharmaceutical investment in antibiotic development diminished 
for various reasons and we are facing a severe situation of no usable antibiotics 
at hand regarding AMR [14]. In the last 40 years only two novel antibiotics, 
linezolid and lipopeptide daptomycin, were clinically approved [15]. Notably, 
just several years after introducing linezolid and daptomycin into clinics, 
resistance in Staphylococcus and Enterococcus emerged [16–18]. New 
antibiotics are thus urgently needed, and a new golden age in antibiotic research 
is probably to solve the current problem. 
 
Fig. 1.3 The race between antibiotic development and bacteria resistance. The 
upper side of the figure shows the antibiotics discovered in each decade; the bars 
and the arrow in the middle indicate the timeline (decades); the bars below the 
decades show the time interval from the introduction of antibiotics on the market 
(upward arrows) to the appearance of resistance (downward arrows). The figure 
is modified and updated from the reference [11]. 
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    Similar to the severe situation of bacterial infection, cancer is another leading 
cause of mortality. According to the World cancer report 2014 from the World 
Health Organization (WHO) [19], there were 14 million new cases with 8.2 
million cancer-related deaths in 2012. Furthermore, the annual cases are 
expected to increase to 25 million in two decades. For a long time, cancer 
treatment relies on surgery coupled with chemotherapy or radiation therapy. 
Although these traditional treatments increased survival rates, they could cause 
side effects such as nausea, diarrhea or even more serious symptoms [20]. Since 
the first tumor targeting drug rituximab has been approved by the U. S. Food 
and Drug Administration (FDA) [21], tumor targeting drugs especially small-
molecule drugs significantly changed cancer treatment [22–26]. For example, 
imatinib (also known as Gleevec, Glivec or STI571) is a lankmark of tumor 
targeting drug, which is a tyrosine-kinase inhibitor approved by FDA in 2001 to 
treat multiple cancers [27, 28]. An ideal anti-cancer agent should possess high 
specificity on certain type of cancer cells with low or physiologically acceptable 
adverse effects. Small molecules from bacteria have great potential to be 
developed as anticancer leading drugs for their low molecular weight and high 
cytotoxicity. For instance, the small molecule epithilone analog ixapebilone was 
approved by FDA to treat metastatic breast cancer, and several of its derivatives 
are currently in clinical trials [29]. In the condition that a small molecule is 
highly toxic to both cancer cells and healthy cells, linking the cell-killing small 
molecule with selective monoclonal antibody for tumor-associated antigen could 
be a strategy to specifically target the tumor cells [30]. As the antibody-drug 
conjugates (ADCs) bind to specific tumor antigen and deliver the conjugated 
active drug inside tumor cells, the anti-tumor effect could be maximized and the 
damage to healthy tissues could be minimized [31]. Recently, two ADCs, 
Brentuximab vedotin and Trastuzumab emtansine, have been marketed and 
several others are in late-phase clinical trial [32, 33]. 
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1.2 Biosynthesis of microbial secondary metabolites 
    Microbial metabolites are traditionally divided into primary and secondary 
metabolites. Primary metabolites such as citric acid, amino acids and fatty acids 
are involved in growth, development and reproduction of organisms. Secondary 
metabolites on the other hand are believed to have important ecological 
functions including being competitive weapons, agents of symbiosis and metal 
transporting agents [34]. Millions of years of evolution in microbes generated a 
myriad of natural products with a variety of structures and bioactivities. Based 
on their structures and biosynthetic origin, secondary metabolites could be 
classified into polyketides (PKs), nonribosomal peptides (NRPs), ribosomally 
synthesized and post-translationally modified peptides (RiPPs), alkaloids, 
terpenoids, glycosides and others [35]. Up to now, the majority of the 
characterized microbial secondary metabolites are PKs, NRPs or hybrids thereof 
which are synthesized by giant enzymes termed polyketide synthases (PKSs), 
nonribosomal peptide synthetases (NRPSs) or hybrid PKS/NRPS systems, 
respectively [36]. This includes clinically used pharmaceuticals, for example, 
erythromycin A (antibacterial), rapamycin (immunosuppressive), avermectin 
(anti-parasitic), lovastatin (cholesterol-lowering) and doxorubicin (anticancer) 
produced by PKSs, as well as cyclosporine (immunosuppressive), tyrocidine 
(antibacterial) and daptomycin (antibacterial) generated by NRPSs. These giant 
enzymes recruit monomers such as simple carboxylic acids (PKSs) and amino 
acids (NRPSs) from primary metabolism or supplied by pathway-specific 
enzymes to assemble structurally diverse natural products. Although PKS and 
NRPS use different types of building blocks, they share a similar biosynthetic 
logic [37, 38].   
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1.2.1 Polyketide biosynthesis 
The earliest genetic study on bacterial antibiotics biosynthesis started around 
1970s when Hopwood was investigating genetics in Streptomyces coelicolor and 
discovered antibiotic biosynthetic and resistance genes on plasmid [39], the 
antibiotic was confirmed to be methylenomycin A shortly afterwards [40]. 
Thereafter the biosynthetic study on actinorhodin and tetracenomycin C 
revealed that their PKSs have similarity with fatty acid synthases (FASs) [41–
45]. Inspired from this, Leadlay and Katz performed the landmark investigations 
on the erythromycin polyketide synthase and dramatically accelerated the study 
on biosynthetic pathways of natural products [46, 47]. 
A minimal PKS module consists of an acyltransferase (AT) domain (~50 
kDa), a ketosynthase (KS) domain (~45 kDa) and an acyl carrier protein (ACP, 
8~10 kDa) [36]. Prior to playing a role, apo-ACP domains have to be primed by 
phosphopantetheinyltransferases (PPTases) [37]. PPTase transfers a thiol-
terminated pantetheinyl arm from Coenzyme A (CoA) to the hydroxyl group of 
the active site serine in apo-ACP to generate holo-ACP (Fig. 1.4). AT domains 
specifically transfer C2, C3 or C4 acyl groups from malonyl-, methylmalonyl- 
or ethylmalonyl-CoA to holo-ACP to form acyl-S-pantetheinyl-ACP. KS 
domains catalyze the chain extension by decarboxylative Claisen condensations 
between monomers and the growing polyketide chain. In addition to the three 
domains essential to chain elongation (AT, ACP, KS), ketoreductase (KR), 
dehydratase (DH) and enoylreductase (ER) domains may also be part of PKSs. 
DH, KS and ER domains function sequentially. DH domain reduces β-keto 
group to β-hydroxyl, KR domain dehydrates β-hydroxyl group to α, β-olefin, 
and ER domain reduces α, β-enyl group to β-methylene [36]. Because of the 
existence or absence of KR, DH or ER domain, the β-keto group of the 
extending chain could be processed as β-ketone, β-hydroxyl, α, β-olefin or β-
methylene (Fig. 1.5). Finally, when an approximate chain length is achieved, the 
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acyl chain is released by a thioesterase (TE) domain via hydrolysis or 
macrocyclization [48]. The released products may undergo further modifications 
such as glycosylation, hydroxylation or methylation by dedicated enzymes to 
obtain bioactivities [49]. According to the domain organization and incorporated 
substrates, PKSs could be characterized into three subgroups: type I, type II and 
type III PKS. Domains in type I PKSs are connected in cis, while in type II 
PKSs they are discrete and function in trans. Instead of using malonyl-S-
pantetheinyl-ACP as substrates by type I and type II PKSs, type III PKSs 
directly use manolyl-CoA as substrates [50]. 
 
Fig. 1.4 Priming of carrier proteins (CP) by phosphopantetheinyltransferases 
(PPTase). Phosphopantetheine arm is transferred from coenzyme A to the 
conserved serine of carrier protein (ACP or PCP domain). 
 
Fig. 1.5 β-keto processing in Type I PKs and FAs. Active domains in each step 
are shown in colors. The modified β-keto is highlighted. 
 
1.2.2 Nonribosomal peptide biosynthesis 
The earliest biochemical investigation on gramicidin S biosynthetic enzymes 
by Lipmann revealed a biosynthetic route which was different from ribosomal-
linked protein synthesis, and amino acids were supposed to be activated as 
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aminoacyl-AMP and transferred to carrier protein [51]. The following research 
unveiled that peptidyl transfer between intermediates was bound to thioester 
linkages of two gramicidin S synthetases [52]. Shortly afterwards peptides were 
discovered attached to pantetheine by a thioester bond in gramicidin S and 
tyrocidine biosynthesis [53, 54]. Almost at the same time the biosynthetic genes 
of the siderophore enterobactin (also known as enterochelin) were identified 
[55–57]. After that the biosynthetic genes of tyrocidine, gramicidin S and 
surfactin were also identified by Marahiel [58–62]. The biochemical 
investigations on enterobactin biosynthesis by Walsh characterized PPTase and 
demonstrated the formation of adenylated substrates, and the biosynthetic model 
of enterobactin was finally uncovered [63–73]. 
The biosynthetic logic from NRPSs is in principle similar to modular PKSs, 
although they apply a different biochemistry for recruitment and condensation of 
substrates. NRPSs use amino acids rather than acyl-CoA as building blocks. The 
core domains of NRPSs are adenylation (A) domain (~50 kDa), peptidyl carrier 
protein (PCP, ~8-10 kDa) and condensation (C) domain (~50 kDa) [36, 74]. 
Similar to PKSs, apo-PCPs are modified to holo-PCP by PPTase before starting 
the assembly (Fig. 1.4). Generally, the A domain selects an amino acid and 
activates it as aminoacyl-adenylate at the expense of ATP and Mg
2+
. The 
aminoacyl-AMP is then attacked by thiol moiety of the holo-PCP to form 
aminoacyl-PCP. The C domain plays the critical role in the elongation of the 
peptide chain. It catalyzes the amide bond (C-N) formation between upstream 
peptidyl-PCP (electrophilic) and downstream aminoacyl-PCP (nucleophilic) 
(Fig. 1.6). When the peptide chain reaches up to the last PCP, it is transferred to 
the TE domain and catalytically released by hydrolysis or intramolecular 
cyclization [35, 48, 75]. Exceptionally, some optional domains such as 
epimerization (E) domain, cyclization (Cy) domain, oxidase (Ox) domain, dual 
condensation/epimerization (C/E) domain, methyltransferase (MT) domain and 
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aminotransferase (AMT) domain etc. could also exist in NRPSs [36]. The E 
domain epimerizes L-amino acids to D-amino acids, its downstream C domain is 
designated 
D
CL domain for the function to condense D-peptidyl donor with L-
aminoacyl acceptor [76]. In some NRPSs, E domain and C domain are replaced 
by an individual bifunctional C/E domain which is equivalent to E-C didomain 
[77]. Similar to C/E domains, Cy domains represents also bifunctional domains. 
Cy domains catalyze amide bond formation between Cys, Ser or Thr and an 
upstream aminoacyl donor. After the condensation event, a heterocycle is 
formed via nucleophilic attack of the Cys, Ser or Thr side chain (thiol or 
hydroxyl group) on the upcoming carbonyl group, followed by elimination of 
water to form thiazoline or (methyl)oxazoline ring structures [36]. These can be 
further converted to thiazole or (methyl)oxazole moieties by Ox domain, 
respectively. Thiazoline could also be reduced to thiazolidine by reductase, as 
exemplified in pyochelin biosynthesis [78]. NRPSs could also integrate MT 
domains to transfer methyl group from S-adenosylmethionine (SAM) to α-amino 
group, or AMT domains to transfer α-amino group from glutamine to the β-
carbon of acyl chain [35, 79]. 
 
Fig. 1.6 C-N bond formation in NRPs biosynthesis. 
 
1.2.3 Biosynthesis of polyketide-peptide hybrid compounds 
    Besides of pure PK or NRP structures, a large number of natural products 
such as epothilone, rapamycin and bleomycin etc. represent polyketide-peptide 
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hybrids [80]. They are manufactured by assembly lines harboring PKS and 
NRPS modules, socalled hybrid PKS/NRPS megasynthetases. However, 
PKS/NRPS systems have a few specific characteristics. Firstly, PPTase should 
be able to trim both ACPs and PCPs in hybrid systems [81]. Secondly, docking 
regions of NRPS domain and PKS domain should crosstalk well [82]. Thirdly 
and most importantly, C domain in PKS/NRPS system should recognize 
polyketide donor, while KS domain in NRPS/PKS machinery should accept 
peptide chain [35]. As hybrid machineries harbor the features of both NRPS and 
PKS, structural diversity can be further increased by combining PKS/NRPS 
biochemistry.  
1.2.4 Lipopeptide biosynthesis 
    Lipopeptides represent a prominent class of NRPSs and PKS/NRPS hybrid 
products exhibiting different biological activities such as antimicrobial, 
antimalarial and anticancer activities [15, 83–85]. They are produced by many 
bacteria including bacillus, pseudomonads, actinomycetes, cyanobacteria and 
myxobacteria. Most of the lipopeptides composed of a cyclic core peptide 
acylated at the N-terminus with a lipid chain, while some others are formed by a 
linear peptide and 1~3 lipid chains [15, 86, 87] (Table 1.1). Majority of the 
lipopeptides like surfactin [88–92], daptomycin [93–96] and telomycin [97] etc. 
are synthesized by NRPSs. While some others eg. cystomanamides [98] and 
myxochromides [99] are synthesized by PKS/NRPS hybrids. In daptomycin and 
telomycin biosynthesis, fatty acid was activated by an independent fatty acyl 
AMP-ligase (FAAL) and loaded to a free-standing ACP. The N-terminal C 
domain then condenses fatty acid with the first amino acid before assembly of 
peptide core. The biosynthesis of surfactin and calcium-dependent antibiotic 
(CDA) is initiated in a similar way, but instead of being carried by an ACP, fatty 
acid is carried by CoA. In some cases, e.g. as described for xenocoumacin [100], 
colibactin [101], zwittermicin [102], didemnin [103] and telomycin [97], lipid 
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chains are introduced only temporarily and are hydrolyzed at a later stage / the 
end of the biosynthesis. 
Table 1.1 The growing class of lipopeptides* 
Lipopeptides Origin Bioactivity 
A21978C Streptomyces roseosporus Antibacterial 
A54145 Streptomyces fradiae Antibacterial 
Amphomycin Actinoplanes friuliensis Antibacterial 
Amphisins Pseudomonas sp. DSS73  Antifungal 
Arthrofactin Pseudomonas sp. MIS38 Antifungal 
Bacillomycins Bacillus subtilis Antifungal 
Carmabin A, 
Dragomabin, and 
Dragonamide A 
Lyngbya majuscula Antimalarial 
Cerexins  
(Linear lipopeptide) 
Bacillus cereus 60–6 and Gp-3 Antibacterial 
Calcium-Dependent 
Antibiotics 
Streptomyces coelicolor Antibacterial 
Cystargamide Kitasatospora cystarginea NB 
Cystomanamides 
(Linear 
glycolipopeptide) 
Cystobacter fuscus MCy9118 NB 
Daptomycin Streptomyces roseoporous Antibacterial 
Echinocandins Aspergillus nidulans var 
echinulatus, Coleophoma empetri 
F-11899, Zalerion arboricola 
Antifungal 
Fengycins Bacillus subtilis,  
Bacillus amyloliquefaciens 
Antifungal 
Friulimicin Actinoplanes friuliensis Antibacterial 
Fusaricidins Paenibacillus spp. Antibacterial and antifungal 
Gavaserin Bacillus polymyxa Antibacterial 
Iturins Bacillus subtilis,  
Bacillus amyloliquefaciens 
Antibacterial and antifungal 
Jolipeptin  
(Linear lipopeptide) 
Bacillus polymyxa ND 
Kurstakin A Bacillus thuringiensis subsp. 
kurstaki HD-1 
Antifungal 
Lichenysins Bacillus licheniformis IM 1307 Antibacterial 
Locillomycins Bacillus subtilis Antibacterial and antiviral 
Marihysin A Bacillus marinus B-9987 Antifungal 
Massetolide A Pseudomonas fluorescens R1SS101 Antifungal 
Mixirins Bacillus sp. Anticancer 
Mojavensin Bacillus mojavensis B0621A Antifungal and anticancer 
Mycosubtilin Bacillus subtilis Antifungal 
Myxochromides Myxococcus sp., Stigmatella sp., 
Hyalangium minutum 
NB 
Octapeptins Bacillus and Antibacterial and antifungal 
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Paenibacillus spp. 
Paenibacterins Paenibacillus sp. OSY-SE Antibacterial 
Pelgipeptins Paenibacillus elgii B69 Antibacterial and antifungal 
Plipastatins Bacillus cereus BMG302-FF67 anti-inflammatory 
Polymyxins Paenibacillus Antibacterial 
Polypeptins Bacillus circulans Antibacterial 
Pumilacidins Bacillus pumilus Antiviral 
Putisolvin Pseudomonas putida PCL1445 Antibacterial 
Puwainaphycin Cylindrospermum alatosporum Cytotoxic 
Ramoplanin 
(Glycolipopeptide) 
Actinoplanes sp. Antibacterial 
Saltavalin  
(Linear lipopeptide) 
Bacillus polymyxa ND 
Subtulene Bacillus subtilis SSE4 Antibacterial and antifungal 
Surfactins Bacillus subtilis Antimicrobial, antiviral, 
antimycoplasma, anticancer and 
anti-inflammatory  
Surotomycin Streptomyces roseosporus Antibacterial 
Syringopeptin Pseudomonas syringae pv. Syringae 
B728a and B301D 
Antibacterial, antifungal and 
phytotoxic 
Syringomycin Pseudomonas syringae pv. Syringae 
B728a and B301D 
Antifungal and phytotoxic 
TAN-1511  
(Linear lipopeptide) 
Streptosporangium amethystogenes Anti- leucopenia 
Telomycin Streptomyces canus C159 Antibacterial 
Tolaasin Pseudomonas tolaasii, 
Pseudomonas sp. NZ17 
Antibacterial, antifungal and 
phytotoxic 
Tridecaptins  
(Linear lipopeptide) 
Paenbacillus polymyxa Antibacterial 
Variochelin Variovorax boronicumulans Siderophore 
Previoprolides  
In this study 
(Lipopeptolide) 
Cystobacter violaceus Cb vi35 Anticancer and antifungal 
Viscosins Pseudomonas libanensis,  
Pseudomonas fluorescens 
Antibacterial and anticancer 
*, the list is summarized from reference [15, 83–87, 97–99, 104–108]. ND, no 
data; NB, no obvious bioactivity at present.  
 
1.3 Genetic engineering and heterologous expression in NP research 
1.3.1 Genetic engineering in natural products research 
    The total synthesis or semi-synthesis of complicated natural products is 
usually challenging. Bioengineering approaches provide possibilities to develop 
modified compounds with improved pharmaceutical properties. In the early 
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stage of natural product research, precursor directed biosynthesis was used to 
generate natural product derivatives [109, 110]. A problem with this method is 
that the modified precursors have to compete with native ones, thus the yield of 
final derivatives is sometimes not prominent. Mutasynthesis could avoid this 
problem by inactivating native precursor supplying genes, but the major 
limitation of this method is the inefficient or unavailable incorporation of 
synthetic precursors due to the limited substrate flexibility of the native enzymes 
[109, 111]. Engineering precursor pathways endogenously or introducing 
tailoring enzymes such as halogenases, glycosylases, acyltransferases and 
sulfotransferases etc. from other gene clusters represent promising opportunities 
for biosynthetic engineering and addressing challenges associated with precursor 
directed biosynthesis and mutasynthesis approaches [109].  
The linear order and composition of domains in modular PKS and NRPS 
determine the structure of the final products. To some extent, it is possible to 
modify the structure specifically and to produce new compound libraries by re-
programming PKS or NRPS machineries via genetic engineering [112]. For 
example, by exchange dapD gene in daptomycin biosynthetic gene cluster with 
cdaPS3 (from CDA gene cluster) or lptD (from A54145 gene cluster), the last 
moiety kynurenine in daptomycin structure was changed into Val, Ile or Trp 
[113]. The same compounds were also obtained by exchanging C-A didomain 
(kynurenine condensation) in the last module of daptomycin biosynthetic 
machinery with the respective part of CDA or A54145 megasynthetase [114]. 
Besides, the binding pocket of A domain contains some specificity-conferring 
codes, the selectivity of A domain could be altered by changing these codes 
[115–117]. Take gramicidin S NRPS for example, W239S mutation in GrsAA 
changed the selectivity from Phe to unnatural aromatic amino acid O-propargyl-
L-tyrosine without effects on catalytic efficiency [116]. Furthermore, directed 
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evolution or random mutagenesis of A domains is also an efficient way to 
generate new derivatives [109, 118].  
Similar modification strategies in NRPS engineering could also be utilized on 
PKSs. Starter units are utilized only once and probably could be tolerated by 
downstream modules in PKSs, consequently non-natural starter units might be 
introduced to PKs by exchange loading modules [119]. Module insertion or 
deletion is also feasible to generate novel polyketide structures. In addition, 
promiscuity of AT and KS domain could be used to introduce non-natural 
extender units. As represented in the engineering of 6-Deoxyerythronolide B 
(DEBS) PKSs, numerous erythromycin analogs were obtained by exchange 
methylmalonyl-specific AT domain to AT domains with different substrate 
specificities [120–122] or by site-directed mutagenesis on AT domain [123, 
124]. Moreover, structural diversity could be achieved by manipulation on DH, 
KR and ER domains. For example, nystatin derivatives with modified antifungal 
and hemolytic activities were generated by site-specific inactivation of the DH, 
KR and ER domains in its PKS [125]. 
1.3.2 Heterologous expression 
Despite the fact that genetic engineering methods were applied in many native 
producers to achieve the production of compounds, genetic manipulation of 
original hosts is in many cases tedious or even infeasible. Especially, many 
myxobacteria are hard to cultivate, and genetic tools are not well developed in 
this kind of bacteria. Although increasing precursor supply, multiplication of 
gene cluster dosage, manipulating regulators and repressing competing 
pathways etc. could be used to elevate the production yield, the expression level 
of many biosynthetic gene clusters in native hosts is low [111, 126]. In addition, 
whole genome sequencing reveals that a large number of gene clusters in native 
producers are “cryptic” or “silent”, and compounds are undetectable or not 
produced in laboratory conditions [127]. Despite that these cryptic gene clusters 
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might be activated by ‘physiological triggers’ and ‘metabolic engineering’ [127], 
the process could be labour-intensive and time-consuming. Moreover, if the 
native producer is slow growing, improvement on it can be more difficult. In 
these conditions, a genetically amenable heterologous host has an advantage in 
characterization of biosynthetic gene clusters, expression of biosynthetic 
pathways, generation of derivatives and increasing production titers [128]. 
Nevertheless, there are also some challenges in heterologous expression. For 
instance, the biosynthetic gene clusters are usually very large. Depending on the 
characteristics of the bacteria, introducing a large DNA fragment into 
heterologous hosts could be difficult. In some bacteria, e.g. myxobacteria, 
plasmids usually could not be sustained in the cells, thus it is necessary to 
integrate the biosynthetic gene cluster into chromosome. Due to the 
complexicity of biosynthetic machineries, megasynthetases may not be 
expressed or correctly folded into functional forms in heterologous hosts. 
Therefore, the compound production level in heterologous hosts could also be 
low or even zero [129, 130]. 
In general, heterologous expression involves five steps: cloning of the 
biosynthetic gene cluster, engineering of expression vector, transformation of 
heterologous hosts, fermentation and product detection (Fig. 1.7). Several 
technologies, such as ligation-dependent conventional cloning and Golden Gate 
assembly [131], Gibson assembly [132], recombination-mediated Red/ET 
recombination [133–136] and transformation-associated recombination (TAR) 
[137, 138] could be utilized to clone the target gene cluster. Based on 
bioinformatic analysis, large gene clusters could also be directly synthesized and 
assembled from small fragments. During de novo DNA synthesis, codon usage 
could be optimized and domain organization in the assembly lines could be 
elaborately designed. Generally, the target gene cluster is cloned to an 
expression vector and a series of genetic manipulations need to be performed on 
1. Introduction 
16 
 
the gene cluster as well as the vector backbone. Suitable genetic elements such 
as resistance genes, replicons or elements for chromosomal integration 
(fragments for homologous recombination, transposon or phage integrase 
cassettes) may have to be added to maintain the gene cluster in heterologous 
hosts. Usually the native promoter of the gene cluster has to be replaced by 
inducible or constitutive promoter to produce target compounds in high titer 
[129]. Sometimes tailoring enzyme encoding and precursor supplying genes also 
need to be added to the expression vector. When the object goes to generate 
derivatives or gene knock-out, mutagenesis may be performed on the expression 
vector. For example, ccdB counterselection combined with Red/ET 
recombination in E. coli could seamlessly introduce mutations in plasmids [115, 
139]. Zinc-finger nucleases (ZFN) [140], the newly-developed transcription 
activator-like effector nucleases (TALENs) [141] and the Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) 
systems [142] also have potential in editing secondary metabolites biosynthetic 
gene clusters. After a series of genetic engineering, the expression vector could 
be introduced into heterologous hosts by transformation, transduction or 
conjugation. The transformants are then cultivated in appropriate media and the 
produced compounds could be detected by liquid chromatography–mass 
spectrometry (LC-MS). The production of target compounds could be validated 
by comparing the retention time, MS and MS/MS fragments with reference 
compounds. In order to verify the chemical structure, target compounds may 
need to be purified and measured by nuclear magnetic resonance (NMR). In case 
of low production in heterologous hosts, the promoter probably has to be 
changed to ensure effective transcription of the biosynthetic gene cluster, and 
optimization of metabolic pathways in heterologous hosts may be required to 
drive appropriate substrates to secondary metabolites biosynthesis. Employment 
of other heterologous hosts may also be taken into account. Conversely, if the 
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heterologous production is successful, the production titer could be improved 
further by optimizing fermentation conditions. 
 
Fig. 1.7 Scheme of heterologous expression. 
 
Driven by the progress in large DNA fragment cloning and DNA synthesis, 
several PKs and NRPs biosynthetic gene clusters have been successfully cloned 
and expressed in heterologous hosts. Take myxobacterial natural products for 
example, epothilone (anticancer), myxothiazole (respiration inhibitor), 
myxochromide S (sufactant), pretubulysin (anticancer) and disorazol (anticancer) 
were successfully produced in heterologous host Myxococcous xanthus [143–
148]. Microbes like Streptomyces, E. coli, Bacillus subtilis, Pseudomonas, 
Mycobacterium smegmatis, Burkholderia, Aspergillus nidulans and 
Saccharomyces cerevisiae etc. also have been used as heterologous host to 
produce secondary metabolites [130, 149–161]. Moreover, Sf9 insect cells and 
even plants are also available to serve as heterologous host [151]. Although they 
have been excavated for nearly a century, bacteria still have great potential in 
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antibiotics discovery. To date only a small fraction of bacteria could be 
cultivated in laboratory conditions [162]. Due to the development of 
metagenome sequencing [163–165] and single-cell genome sequencing [166], 
the genetic information of novel antibiotics biosynthetic gene clusters in 
unculturable microorganisms became accessible. Introducing the biosynthetic 
gene cluster of the target compound into heterologous host could be a versatile 
method to explore this hidden world. 
 
1.4 Myxobacteria and natural products 
Myxobacteria are Gram-negative bacteria and most of them are soil dwelling 
microbes [167]. They belong to δ-proteobacteria in the order Myxococcales and 
could behave in both unicellular and multicellular forms [168]. One of their 
characteristics is gliding and swarming on surfaces of matrix (Fig. 1.8). Under 
starvation vegetative cells differentiate into myxospores and form fruiting 
bodies. They are also renowned for predatory of other microbes by producing 
exoenzymes and bioactive small molecules [168–172]. Although the earliest 
discovery of myxobacteria was in 1892 [173], extensive study on this kind of 
bacteria started from 1940s. Usually myxobacteria are slow growing in 
laboratory conditions, and most strains could not grow in homogenous 
suspensions, so in many cases it requires a long period to characterize natural 
products from myxobacteria [167]. Over the last decades myxobacteria have 
grown up to be an important source of secondary metabolites besides of 
actinomycetes, bacillus, pseudomonads and fungi. To date more than 100 core 
structures and around 600 derivatives have been identified from myxobacteria 
[174]. The bioactivities of these compounds are diverse from anti-infective to 
cytotoxic, and their modes of actions (MOA) are distinctive [175–177] (Fig. 1.9).  
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Since the genome of Myxococcus xanthus DK1622 been sequenced in 2006 
[178], around 25 myxobacteria genomes have been sequenced. Their genome 
sequences are available in the NCBI Genome database. Most of their genome 
sizes are greater than 5 Mb. The genome size of Sorangium cellulosum So ce56 
even reached up to 13 Mb. The GC content of the myxobacteria genomes is 
generally very high (63% ~ 75%). To date, around forty biosynthetic gene 
clusters from myxobacteria have been published, and around half of them are 
PKS/NRPS hybrids (Table 1.2). Deeper investigations on genome, proteome and 
metabolome of myxobacteria uncovered their great potential in novel structure 
discovery and biosynthetic pathway expression [164, 179–182]. 
 
Fig. 1.8 Myxobacteria colonies and fruiting bodies. 
 
Table 1.2 Biosynthetic gene clusters identified from myxobacteria* 
Compound Producer 
Biosynthetic 
Type 
Saframycin Myxococcus xanthus DSM504/15 NRPS 
Soraphen Sorangium cellulosum So ce26 PKS 
Myxovirescin  Myxococcus xanthus DK1622 PKS/NRPS 
Myxothiazol Stigmatella aurantiaca DW4/3-1 PKS/NRPS 
Epothilone Sorangium cellulosum So ce90  PKS/NRPS 
Myxochelin Stigmatella aurantiaca Sg a15 NRPS 
Myxalamid Stigmatella aurantiaca Sg a15 PKS/NRPS 
Stigmatellin Stigmatella aurantiaca Sg a15 PKS 
Melithiazol Melittangium lichenicola Me l46 PKS/NRPS 
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Tubulysin Angiococcus disciformis An d48 PKS/NRPS 
Disorazol Sorangium cellulosum So ce12 PKS/NRPS 
Myxochromide S Stigmatella aurantiaca DW4/3-1 PKS/NRPS 
Cystothiazole Cystobacter fuscus AJ-13278 PKS/NRPS 
Chivosazol Sorangium cellulosum So ce56 PKS/NRPS 
Myxochromide A Myxococcus xanthus DK1622 PKS/NRPS 
Chondramide Chondromyces crocatus Cm c5 PKS/NRPS 
Ambruticin Sorangium cellulosum So ce10 PKS/NRPS 
Jerangolid Sorangium cellulosum So ce307 PKS 
Aurachin Stigmatella aurantiaca Sg a15 PKS 
Spirangien Sorangium cellulosum So ce90 PKS 
Etnangien Sorangium cellulosum So ce56 PKS 
DKxanthene 
Myxococcus xanthus DK1622 and  
M. xanthus DK1050 
PKS/NRPS 
Aurafuron Stigmatella aurantiaca DW4/3-1 PKS 
Ajudazol Chondromyces crocatus Cm c5 PKS/NRPS 
Chondrochloren Chondromyces crocatus Cm c5 PKS/NRPS 
Thuggacin 
Sorangium cellulosum So ce895 and 
Chondromyces crocatus Cm c5 
PKS/NRPS 
Leupyrrins Sorangium cellulosum So ce690 PKS/NRPS 
Rhizopodin Stigmatella aurantiaca Sg a15 PKS/NRPS 
Myxopyronin Myxococcus fulvus Mx f50 PKS 
Corallopyronin Corallococcus coralloides B035 PKS/NRPS 
Sorangicin S. cellulosum So ce12 PKS 
Microsclerodermins Sorangium and Jahnella species PKS/NRPS 
Gephyronic acid Cystobacter violaceus Cb vi76 PKS 
Phenylnannolone A Nannocystis pusilla B150 PKS 
Crocacin Chondromyces crocatus Cm c5 PKS/NRPS 
Cystomanamide Cystobacter fuscus MCy9118 PKS/NRPS 
Dawenol Stigmatella aurantiaca DW4/3-1 PKS 
Macyranone Cystobacter fuscus MCy9118 PKS/NRPS 
Bengamide Myxococcus virescens ST200611 PKS/NRPS 
Chlorotonil Sorangium cellulosum So ce1525 PKS 
Haliangicin Haliangium ochraceum SMP-2 PKS 
*, the table is summarized from [98, 180, 181, 183–198]. 
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Fig. 1.9 Selected bioactive compounds from myxobacteria. 
 
1.5 Outline of this dissertation 
The topic of this thesis dealt with biosynthesis and heterologous production of 
vioprolides from the myxobacterium Cystobacter violaceus Cb vi35 (Fig. 1.10). 
Vioprolides are cyclic peptolides with remarkable anticancer and antifungal 
activities [199] (Fig. 1.11). An unprecedented moiety trans-(2S, 4R)-4-
methylazetidine-carboxylic acid (Maz) is harbored by vioprolide A and C, while 
L-glyceric acid is also uncommon in nature. Vioprolides A, B and C are found 
highly cytotoxic to mammalian cells but with low anti-fungal activity. 
Conversely, vioprolide D shows high activity to a broad spectrum of fungi and 
yeasts but is less toxic against mammalian cells. Consequently, they have great 
potential to be developed as anti-fungal drugs and anti-cancer agents. In addition, 
vioprolides are also possible to be used to treat various diseases and disorders by 
enhancing the level of interferon α and β (US Patent: US 2010/0028298 A1 and 
US20110173707). Due to the low amount of vioprolides produced by the native 
producer, research on their mode of action has not met with success. Although 
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several structural fragments of vioprolides such as E-Dhb-Thiazoline-Pro-Leu 
and azetidinyl-thiazoline fragments could be synthesized chemically [200, 201], 
total synthesis of vioprolides is not established yet. 
 
Fig. 1.10 Different life stages of C. violaceus Cb vi35. 
 
 
Fig. 1.11 Chemical structures of vioprolides. 
 
Since the isolation of vioprolides from the myxobacterium C. violaceus Cb 
vi35, little is known about their biosynthetic mechanism. In this dissertation, the 
in-depth sequence analysis and retro-biosynthesis prediction on the Cb vi35 
genome gave insights to the vioprolide biosynthetic gene cluster. In order to 
identify the previoprolides, we performed isotope labeling in C. violaceus Cb 
vi35. For the purpose of confirming the vioprolide biosynthetic gene cluster, we 
tried to clone the vio gene cluster from Cb vi35 genome and express it in 
heterologous hosts. Constitutive promoters were applied to drive the vio gene 
cluster in heterologous systems to increase the production yield, and site-
directed mutagenesis was carried out to generate vioprolide analogues. 
Meanwhile, we tried to isolate vioprolide derivatives and previoprolides from 
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heterologous system and verify their structures by NMR. Furthermore, in vitro 
biochemical characterizations were performed to investigate the mechanism of 
assembly initiation and the unusual glycerate esterification process. The results 
are described and discussed in Section 2 and Section 3. 
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Abstract 
Vioprolides, produced by Cystobacter violaceus Cb vi35, are myxobacterial 
peptolides notable for their prominent cytotoxicity and anti-fungal activity. 
While their structures were reported back in 1996, the biosynthesis, in particular 
that of the uncommon structural element 4-methylazetidine-carboxylic acid 
(Maz) remained elusive. We successfully established heterologous expression 
systems in Myxococcous xanthus DK1622 (ΔmchA), Burkholderia sp. 
DSM7029 and Pseudomonas putida KT2440 for the vioprolide biosynthetic 
gene cluster which enabled us to study the biosynthetic machinery. Gene 
inactivation studies in these hosts allowed us to identify the genes involved in 
vioprolide biosynthesis and the gene responsible for the formation of pipecolic 
acid which is indispensable for the biosynthesis of vioprolides A and B. A 
discrepancy between the biosynthetic gene cluster and the known vioprolide 
structures was revealed as a hydrolytic maturation process. Vioprolides were 
found to be synthesized as acylated precursors by nonribosomal peptide 
synthetase (NRPS) machinery containing an unusual starter domain. After 
assembly, these acylated precursors were cleaved and only the matured 
vioprolides were exported into the extracellular medium. An unusual C domain 
was identified to catalyze the condensation between fatty acids and glycerate, 
which was characterized by in vitro biochemical analysis. 
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2.1 Introduction 
    Vioprolids are striking examples for the structural diversity that can be found 
in myxobacterial secondary metabolites (Fig. 2.1). The peptolide produced by 
the myxobacterium Cystobacter violaceus Cb vi35 are one of the very few 
examples of bacterial metabolites containing an azetidine ring and are 
interesting compounds for further research due to their remarkable cytotoxic, 
antifungal and immunomodulatory activities (US patents: US20100028298 and 
US20110173707) [1]. In view of the exerted effects, it seems likely that several 
independent targets are affected by vioprolides and the combination of anti-
fungal and immunomodulatory activity is noteworthy. Fungal infections receive 
less attention than the more threatening bacterial infections in addition to the 
availability of limited data regarding the epidemiology of fungi related 
infections [2]. However, this data suggests that this issue is underestimated and 
that the growing number of immunocompromised patients is highly threatened 
by invasive mycoses [3]. We think that vioprolide D is a promising compound 
following a one-compound-multiple-targets strategy for invasive fungal 
infections, since it acts as an anti-fungal agent in addition to inhibiting interferon 
response. This combination is noteworthy, since it has been shown that type I 
interferon-signaling mediates the lethal hyper-inflammatory response during 
systemic mouse infections with C. albicans [4]. To further elaborate on the 
mode and the mechanism of action, a steady supply of compound is necessary.  
    In this study we established several heterologous hosts successfully producing 
vioprolides with one host producing at significantly higher titers than the natural 
producer. The genomic data available for Cb vi35 allowed us to identify the 
biosynthetic gene cluster. The biosynthetic model for vioprolide formation was 
in discrepancy with the reported structures as the presence of a fatty acid ligase 
and a bifunctional glyceryl transferase/phosphatase belonging to the HAD 
superfamiliy was found to initiate the biosynthesis. This contradiction led to the 
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identification of acylated vioprolides that were exclusively found in the cell 
pellet. Next to the cystomanamides, this is to our knowledge the only other 
example of an FkbH-like domain in an NRPS module. The acyl group that is 
introduced by this unusual initiation module likely represents another example 
of a hydrolytic maturation process.  
 
Fig. 2.1 Chemical structures of vioprolides 
 
2.2 Results & Discussion 
Identification of acylated vioprolides 
    In the course of our efforts to shed light on the biosynthesis of vioprolides, we 
identified a fatty acid ligase in the biosynthetic cluster that is in discrepancy 
with the known structures of vioprolides A-D. To identify these putative acyl 
derivatives, we screened data obtained in feeding studies of C. violaceus Cb 
vi35 for the presence of compounds that also exhibited the corresponding mass 
shifts. Interestingly, no such compounds could be found in the culture 
supernatants, but in the cell pellets (supplementary). The incorporation of 
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L-methionine-(methyl-
13
C), L-methionine-
13
C4,
15
N, L-methionine-(methyl-d3) and 
L-threonine-
13
C4,
15
N was observed for a range of four compounds with retention 
times shifted to high acetonitrile content (supplementary). These compounds 
were subsequently assigned based on exact mass and fragmentation pattern as 
vioprolide A/B and vioprolide C/D acylated derivatives that were not known 
before. The successful purification and structure elucidation of these derivatives 
was only possible after establishing a heterologous expression system that 
enabled us to isolate a sufficient amount of compound. The presence of the acyl 
derivatives was found in agreement with the biosynthetic gene cluster found in 
C. violaceus Cb vi35, details regarding the biosynthesis will be given in the next 
paragraph. No fatty acids other than saturated C16 and C17 were found in the 
natural producer as well as the heterologous hosts which is in agreement with 
reported lipid profiles of myxobacteria [5–7]. Four precursors could be purified 
from 10 L cultures of M. xanthus::Ptet-vio with yields between 1.2 mg and 11.9 
mg. The most prominent precursor was hydrolyzed by sodium hydroxide and the 
fatty acyl component was identified as iso-C17:0 by GC-MS (supplementary). 
Structure elucidation by 1D and 2D NMR experiments revealed the structure as 
vioprolide B with an iso-C17 fatty acid chain on the free hydroxyl group of 
glyceric acid (supplementary). The bioactivity assay showed that previoprolide 
B retained the high cytotoxicity on HCT-116 colon cancer cells (IC50 = 0.12 
µg/mL), while no obvious activity against Candida albicans and Mucor hiemalis 
(IC50 > 64 µg/mL) was found, which was consistent with the bioactivity of 
vioprolide B. The fact that no obvious change in bioactivity could be found for 
the acylated vioprolide suggests the acylation does not serve as a pro-drug 
mechanism but rather serves a directed transport mechanism, since acylated 
variants were exclusive to the cell pellet. 
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Identification and sequence analysis of the vio gene cluster 
The genome sequence of C. violaceus Cb vi35 was searched in silico for 
secondary metabolite gene clusters using the antiSMASH platform revealing a 
region of 56.2 kb (68.9% GC content) that, based on retro-biosynthetic 
considerations, putatively contains the vioprolide gene cluster [8, 9]. The core 
biosynthetic assembly line contains 10 modules harboring 33 domains (Fig. 2.2) 
and is flanked by a putative ornithine cyclodeamidase (vioZ) upstream of vioA 
and a putative biosynthetic protein (orf3) downstream of vioD. The biosynthesis 
is driven by 2 unusual modules and 8 NRPS modules encoded on the four genes 
vioA-vioD. After antiSMASH analysis, annotations were further refined by 
alignment with the non-redundant protein database. The resulting in silico based 
assignments are summarized in (supplementary). Modules 3, 4, 6, 9 and 10 are 
standard NRPS-modules for which in silico analysis of A domain specificities is 
in agreement with the incorporated amino acids [10]. The A3 domain activates L-
Pro and probably also 4-methylazetidine carboxylic acid (Maz). Its binding 
pocket (DVQCLSEVTK) is different from APro domains (DVQLIAHVVK). 
Besides, several active residues of the Pip/Pro activating (A6) domain 
(DIQYYAQVVK) are also different from reported Pip or Pro activating domain. 
The non-standard modules were subject to a detailed analysis. The identified 
cluster was heterologously expressed in three different hosts for production 
optimization and gene knock-out experiments. Knock-out experiments were 
carried out in Myxococcus xanthus DK1622 and Burkholderia sp. DSM7029 as 
a phylogenetically distant host. Ancillary genes orf3 – orf9 were knocked out 
one by one as well as all at once, however no effect on the production of 
vioprolides in both heterologous hosts was observed and these genes were thus 
deemed not involved in the biosynthesis of vioprolides (supplementary).  
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In vitro characterization of module 1 
    The initiating module starts with a FAAL (fatty acid AMP ligase) domain 
which was characterized to activate and introduce long chain fatty acids in both 
polyketide and nonribosomal peptide biosynthesis by activation and loading of 
fatty acids to ACP domains [11–13]. Since the known vioprolides do not contain 
fatty acids, this led us to believe that the acylation is an intermediate means to 
facilitate compound export. Several examples of hydrolytic maturation in 
secondary metabolite biosynthesis were recently reported. In the biosynthesis of 
xenocoumarin [14], heronamide [15], peanilamicin [16], pyoverdine [17], 
colibactin [18], naphthyridinomycin [19], quinocarcin [20] and telomycin [21] a 
hydrolytic removal of N-amino-acyl chains was shown to serve as a maturation 
process that was also responsible for the observed discrepancy between the 
biosynthetic gene cluster and the structure of the corresponding compounds in 
some cases. Proteolytic maturation was also shown for didemnin [22], 
saframycin [23] and nocardicin A [24] biosynthesis but the corresponding 
proteases are unknown. A comprehensive overview of maturation processes in 
natural compounds biosynthesis can be found in recent reviews [25, 26].  
In order to validate the C domain catalyzed glycerate esterification, the full-
length FAAL-ACP-C-FkbH-PCP (FkbH-PCP, 205 kDa), FAAL-ACP, and ACP 
were expressed and purified from E. coli (supplementary). FAAL-ACP was 
initially incubated with MtaA (PPTase) and fatty acids. The reaction without 
MtaA, ATP or fatty acid served as a negative control. To our surprise, we only 
found the loading of palmitic acid in the presence of other fatty acids and even 
when no fatty acid was added to the assay (supplementary). Once apo-FAAL-
ACP was transformed to holo-FAAL-ACP by incubation with MtaA and ATP, 
C16:0 was transferred completely. Without the presence of ATP, the loading of 
palmitic acid was incomplete (supplementary). These results suggested the 
presence of an internal activated fatty acid bound to the FAAL domain and that 
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the fatty acyl loading is ATP-dependent. As previously reported, an acyl 
adenylate binding pocket exists in FAAL [23]. We hypothesized that FAAL 
activates palmitic acid, the most prominent fatty acid [27] in E. coli, and held it 
in its hydrophobic pocket. In order to get rid of this intrinsic fatty acid, we first 
attempted to purify soluble FAAL-ACP from inclusion bodies by denaturation 
and refolding but failed. In a second approach we attempted to chemically 
offload the fatty acid with cysteamine as reported by Belecki et al. to enable 
subsequent loading assays [28]. The palmitoyl chain could be successfully 
offloaded but at the same time excessive disulfide bridges formed between 
FAAL-ACP and cysteamine which could not be fully converted even after 3 
hours of incubation at 37 °C with DTT. The third and successful strategy to 
obtain FAAL-ACP without innate fatty was an in trans catalytic approach. The 
binding pocket of the FAAL domain was initially emptied by transferring the 
internal palmitoyl chain to the downstream ACP of FAAL-ACP. The pocket 
vacant FAAL-ACP was then utilized for in trans transfer of C16:0, C17:0, iso-C16:0 
and iso-C17:0 to the discrete holo-ACP. The fatty acids were restricted to these 
four species in consideration of the identified compounds. Characterization of 
the protein loadings by LC-MS revealed iso-C17:0 as the favored substrate (Fig. 
2.3). This result is consistent with the structure of previoprolide B which was 
identified as the most prominent precursor.  
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Fig. 2.3 Biochemical characterization of the module 1. (A) scheme of enzymatic 
reaction. The binding pocket of FAAL-ACP was emptied by incubation with 
MtaA, ATP and CoA. The pocket free FAAL-ACP was used to load other fatty 
acids to the discrete ACP; (B) LC-MS analysis of fatty acids loaded on holo-
ACP. 
 
In vitro characterization of module 1&2 
The second domain of module 2 was annotated as FkbH-like domain 
belonging to the HAD-superfamily which is expected to load and 
dephosphorylate D-1, 3-bisphosphoglycerate to afford a glyceryl moiety on the 
PCP1 domain. Such bifunctional glyceryl transferases/phosphatases were 
reported in other NRPS/PKS assembled natural products such as FK520, 
oxazolomycin, tautomycin, tetronomycin, RK-682, zwittermicin A, FR901464, 
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phormidolide, cystomanamide and pellasoren [29–38]. Most of the reported 
FkbH-like proteins serve to provide a variety of extender or starter units to PKS 
biosynthetic machinery with cystomanamide as the only example of an FkbH-
like protein in a NRPS setting. To the best of our knowledge, this is the first 
example of an FkbH domain initiated NRPS assembly line, further underlining 
the generality of glyceric acid as a building block. In a detailed study of the 
OmzB protein by Dorrestein et al. it was shown that the first step involved in the 
process is the loading of D-1, 3-bisphosphoglycerate [31]. Vioprolides, however 
contain an L-configured glycerate moiety which fits well with the E1 domain that 
putatively isomerizes D-glycerate to L-glycerate. An alignment of the C domains 
with other C domains (supplementary) led to a prediction that is contradicting 
the known structures. A possible reason for this apparent discrepancy is that the 
underlying data used for alignment is lacking the critical number of C domains 
with the same substrate specificity. Validation of the C domain catalyzed 
glycerate esterification was initially attempted on the intact protein level. In 
vitro reconstitution assay were done with heterologously expressed FAAL-ACP-
C-FkbH-PCP (1), FAAL-ACP (2), C-FkbH-PCP (3), FkbH-PCP (4) and PCP (5). 
In cis assays using 1 could not be successfully established due to the instability 
of 1 under various buffer and reaction conditions. Combinations of 1 and 3, 1 
and 4, 1 and 5, and 2 and 3 were used for in trans catalysis, however no fatty 
acyl glycerate transfer to the holo-PCP could be detected. To substantiate the 
putative condensation of the fatty acid with glyceric acid, we decided to 
characterize the enzyme bound substrates by making use of the offloading 
strategy reported by Belecki et al. Briefly, protein samples of 1 were incubated 
with D-3-phosphoglyceric acid , phosphoglycerate kinase (PGK), MtaA, ATP, 
CoA and fatty acid. After this step, samples were further incubated with 
cysteamine at 4 °C overnight to promote the chemical release of the bound 
substrates which were then extracted and measured by LC-MS/MS. Since it was 
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known that C16:0 was inherent to the FAAL domain, the incorporation of fatty 
acids other than palmitic acid relied on a certain turnover once cysteamine was 
added and thus also relied on the presence of PGK. FAAL bound fatty acids 
were found as single compounds while two species with different retention 
times were found for each fatty acyl glyceryl derivative with identical MS/MS 
fragmentation pattern and accurate mass (Fig. 2.4).  These two species are likely 
the regioisomers formed via 2, 3-acyl migration – a process that is reported to 
facilely take place under various experimental conditions [39–42]. We also 
found the C16:0 acylated glyceric acid derivative in the absence of all enzymes 
but 1 indicating an almost complete attachment of glycerate in E. coli. As 
expected, the presence of glyceric acid derivatives of C17:0 and iso-C17:0 could 
only be detected in the presence of PGK and phosphoglycerate (Fig. 2.4). 
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Fig. 2.4 Biochemical characterization of module 1&2. (A) diagram of offloading 
intermediates from FAAL-PCP; in the first round of reaction, the innate C16:0 
was transferred to the ACP and was subsequently condensed with glycerate; 
after offloading C16:0-glycerate and the inherent C16:0, the net FAAL-PCP went 
to the second round of reaction with C17:0 or iso-C17:0 and reacted in a similar 
way; (B) structures of the offloaded protein-bound intermediates in various 
reaction systems; (C) UPLC-HRMS analysis of the offloaded intermediates; 
reaction systems: i) FAAL-PCP control without other enzymes and substrates; ii) 
FAAL-PCP + C17:0 + MtaA + ATP + PGK; iii) FAAL-PCP + iso-C17:0 + MtaA + 
ATP + PGK; iv) FAAL-PCP + MtaA + ATP + PGK (without fatty acid); v) 
FAAL-PCP + iso-C17:0 + MtaA + ATP (without PGK); the MS/MS patterns of 4 
and 5 as well as their regioisomers (4’ and 5’ respectively) are shown; mass 
accuracy is below 100 ppb.  
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Overexpression of the vio gene cluster in heterologous hosts 
    The myxobacterium Myxococcus xanthus served as heterologous host to 
produce several compounds as reported previously [43–49]. The heterologous 
host M. xanthus DK1622 (ΔmchA) used in this study is derived from M. xanthus 
DK1622 in which the native myxochromide A gene cluster was deleted. After 
integration of p15A-Ptet-vio into the chromosome of M. xanthus DK1622 
(ΔmchA), several transformants M. xanthus::Ptet-vio were cultivated in CTT 
medium to test the production of vioprolides. The UHPLC-ESI-HRMS analysis 
revealed the production of four major compounds. The first compound showed 
the same retention time, molecular mass and MS/MS fragmentation patterns as 
vioprolide D, and the third compound was consistent with vioprolide A/B (Fig. 
2.5). However, the retention time of the second and the fourth compounds did 
not match the reported vioprolides, although their molecular mass and MS/MS 
fragmentation patterns are identical with vioprolide C/D and A/B, respectively. 
These compounds were subsequently purified and validated to be vioprolides by 
NMR (supplementary). The first and the third compounds turned out to be 
vioprolide D and B, while the second and the fourth compounds are the 
regionisomers of vioprolide D and B. Quantitative analysis showed the 
production yield of vioprolide B (39.6 mg/L) and D (41.6 mg/L) was 6-fold and 
9-fold with half producing time as in the native producer (supplementary). In 
addition, considering Ptn5 promoter significantly improved the production of 
myxochromide S in M. xanthus [45], we replaced the Ptet promoter in p15A-
Ptet-vio with Ptn5 promoter to study whether the production titer of vioprolides 
could be elevated. The resulting expression vector p15A-Ptn5-vio was 
transformed into M. xanthus DK1622 (ΔmchA). The UHPLC-ESI-HRMS 
analysis showed that all vioprolides were produced in the mutant M. 
xanthus::Ptn5-vio, however, the production yield of vioprolide B (10.0 mg/L) 
and D (6.7 mg/L) was lower than M. xanthus::Ptet-vio. 
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Burhkolderia is a Gram-negative genus revealing great potential in natural 
products biosynthesis [50–52]. Here we also studied the feasibility to express the 
vio gene cluster in Burkholderia. Both p15A-Ptet-vio and p15A-Ptn5-vio were 
integrated into the genome of Burkholderia sp. K481-B101 (ATCC 53080; 
DSM 7029) [53, 54]. The transformants B. sp. DSM7029::Ptet-vio and B. sp. 
DSM7029::Ptn5-vio were fermented in CYCG medium. UHPLC-ESI-HRMS 
analysis revealed the production of vioprolide B and D (Fig. 2.5), although only 
vioprolide B was the prominent product. Quantitative analysis showed that B. sp. 
DSM7029::Ptet-vio and B. sp. DSM7029::Ptn5-vio produced 16.9 mg/L and 
20.4 mg/L vioprolide B, respectively. Our results suggest the great potential of 
Burkholderia to produce secondary metabolites as heterologous host. The 
vioprolide expression vectors were also introduced into Pseudomonas putida 
KT2440 which is widely used as heterologous host to produce natural products 
[53], but only low amounts of vioprolide B and D were produced 
(supplementary). In addition, p15A-Ptet-vio was transformed into E. coli 
GB2005 (MtaA) [56] and E. coli Nissle 1917 [54], but no vioprolide production 
was observed in various conditions (data not shown). 
 
Fig. 2.5 UHPLC-ESI-HRMS analysis of vioprolides from M. xanthus and 
Burkholderia mutants. Extracted ion chromatogram (EIC) m/z of vioprolides 
(vioprolide D and isomer, [M+H]
+ 
= 849.4; vioprolide B and isomer, [M+H]
+ 
= 
863.4) were analyzed for M. xanthus DK1622 (ΔmchA) mutants (A) and B. sp. 
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DSM7029 mutants (B). C. violaceus Cb vi35 was set as reference, M. xanthus 
and B. sp DSM7029 without vio gene cluster were set as negative control (NC). 
Intensity is set to the same range. 
 
Mechanism of Maz formation 
    Only several natural products containing azetidine rings are known, and even 
less information can be found regarding the biosynthetic origin of the four-
membered heterocycle. Among the plant derived compounds mugineic acid [57], 
calydaphninone [58], gelsemoxonine [59] and azetidine-2-carboxylic acid, 
biosynthesis studies showed that azetidine is formed from 2, 4-diaminobutyric 
acid which itself originates from S-adenosylmethionine (SAM) or homoserine 
[60]. The biosynthesis of the sponge derived compound penaresidin [61] and the 
fungal metabolites okaramine B [62] and taichunamide [63] is completely 
unknown. The azetidine ring of polyoxins produced by Streptomyces cacaoi is 
formed by heterocyclization of isoleucine [64–66]. We performed a BLAST 
search of the three genes polC, polE and polF that were suspected to be 
responsible for azetidine formation in polyoxins, but no matches were found in 
the genomes of C. violaceus Cb vi35 and M. xanthus DK1622. The four-
membered azetidine ring in penicillin and clavulanic acid was formed via 
intramolecular cyclization catalyzed by dedicated synthase [67], whereas the β-
lactam in nocardicin A was formed by an unusual C domain catalyzed 
intermolecular cyclization [68]. Unexpectedly, C. violaceus Cb vi35 didn’t 
produce vioprolide A and C under the conditions applied in our experiment, so it 
is not possible to identify the precursor of Maz by isotope feeding. It seems that 
certain conditions, e.g. chemical signals from environment, are essential to 
activate the expression of Maz forming enzymes. We are trying to cultivate C. 
violaceus Cb vi35 in various conditions to get the production of vioprolide A 
and C. As vioprolide A and C were not produced in heterologous hosts, the Maz 
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forming genes may not exist in the cloned vio gene cluster. It is also possible 
that certain cultivating condition is needed to activate the expression of Maz 
forming enzymes in heterologous systems. Therefore, the mechanism of Maz 
formation is still elusive at present. 
Generation of new derivatives by site-directed mutagenesis 
The substrate specificities of the A domains was predicted by NRPSpredict2 
and the putative active pockets were compared with specificity-conferring code 
[69, 70] (supplementary). Interestingly, the active residues of the A1 domain 
(DVWHLSLIEK) differ from common AAla domains (DLLFGIAVLK) but are 
highly similar to ASer domains (DVWHLSLIDK), resulting in Ser as the 
predicted specificity. The only difference of A1 to Ser activating A domains is 
found at positon 331, where a glutamic acid is found in place of an aspartic acid. 
This led us to the hypothesis, that an E331D mutation of the A1 domain could 
change the substrate specificity to Ser. To test this hypothesis, the Glu331 
encoding codon GAG was changed to GAC by site directed mutagenesis via 
ccdB counter selection. The mutant p15A-Ptet-vioArecov-A1E331D was 
transformed into M. xanthus DK1622 (ΔmchA) and fermented in CTT medium 
with supplement of pipecolic acid. HPLC-MS analysis showed that vioprolides 
were produced as hydroxylated forms (vioprolide B1~D1) (Fig. 2.6), eluting at 
earlier retention times compared to the vioprolides B and D. Notably, the 
mutated A1 domain retained the capability to incorporate Ala, as the vioprolides 
B and D were still produced in low amounts. To validate the replacement of 
alanine by serine, we purified 1.4 mg vioprolide B1 and 2.6 mg vioprolide D1 
from 10 L cultures and the structure of vioprolide D1 was elucidated using NMR 
spectroscopy (supplementary). Surprisingly, the pronounced cytotoxicity of 
vioprolide B was lowered by a factor of 100 by hydroxylation. The fundamental 
reason of this observation remains hidden, as both the molecular target and the 
mode of action of vioprolide B are unknown at present. Nevertheless, the 
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introduction of a second hydroxyl group enables the generation of a larger 
variety of derivatives. Inspired by the engineering of the NRPS product 
pyochelin where the inactivation of an NMT domain by mutation of a conserved 
Gly into Arg led to the production of N-desmethyl derivatives [71], we tried to 
generate N-desmethyl vioprolides in a similar way. The NMT domain in module 
10 was inactivated by mutating the conserved Gly encoding codon GGA to the 
Arg encoding codon CGA and the resulting mutant p15A-Ptet-vioArecov-
NMTmut was transformed into M. xanthus DK1622 (ΔmchA). LC-MS analysis 
revealed the production of desmethyl-vioprolides (vioprolide B2~D2) (Fig. 2.6) 
at significantly lower levels than the original vioprolides. We therefore decided 
to limit the characterization to LC-MS and MS/MS. A simultaneous mutation of 
the A1 domain and the NMT domain led to the production of hydroxyl-
desmethyl-vioprolides (vioprolide B3~D3) in M. xanthus (Fig. 2.6) but the 
production was accompanied by a further drop in yield. As reported in pyochelin 
biosynthesis, inactivation of an NMT domain affected the chain release from the 
assembly line. The yield reduction of desmethyl-vioprolides might have resulted 
from stagnant chain release, which might be overcome by deletion of the NMT 
domain. 
 
Fig. 2.6 UPLC-HRMS analysis of vioprolides and derivatives in M. xanthus 
mutants. B and D, vioprolide B and D; B1 and D1, vioprolide B1 and D1 from 
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A1E331D mutants; B2 and D2, vioprolide B2 and D2 from NMT mutants; B3 
and D3, vioprolides B3 and D3 from A1E331D and NMT dual mutants; iso-B, 
iso-D, iso-B1 and iso-D1, isomers of the respective vioprolides. EIC m/z 
([M+H]
+
) of the respective compound is shown at the right side. Intensity is set 
to the same range. 
 
Conclusion 
    Vioprolides were shown to be synthesized on an NRPS machinery with an 
uncommon initiation module that is responsible for the formation of acylated 
derivatives. We have shown that the FAAL domain activates long chain fatty 
acids and loads them onto the ACP domain. The FkbH domain transfers D-1, 3-
bisphosphoglycerate onto PCP1 domain and the unusual C1 domain couples 
these substrates to deliver a 2-acyl-glyceric acid to the following NRPS 
machinery. The resulting acylated derivatives could only be found in the cell 
pellet which we believe to be attributed to a hydrolytic maturation process for 
facilitated compound export. In feeding studies we could prove that the carbon 
skeleton of methyl-azetidine is derived from proline, but no responsible protein 
could be identified in the cluster. The established heterologous expression 
system allowed an approx. 8-fold higher production level in half the time. Site 
directed mutagenesis of the A1 domain of module 3 and the NMT domain in 
module 10 enabled us to generate analogues that, especially in the case of 
hydroxylation, broaden the scope of possible semi-synthetic derivatives. Our 
work sets the stage for future research to reveal the mode of action. 
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2.3 Experimental section 
Bacterial strains, primers and culturing conditions 
    Strains and primers used in this study are shown in supplementary. E. coli 
GB2005 and HS996 were used for cloning, and E. coli GB05-Red was used for 
Red/ET recombination [72]. E. coli GBred-gyrA462 was used for site-directed 
mutagenesis [73]. E. coli Rosetta (DE3) and E. coli BL21 (DE3) were used to 
express proteins for in vitro assay. E. coli was cultivated at 37 
o
C in low salt 
Luria-Bertani (LB) broth (Trypton 10 g/L; Yeast extract 5 g/L; NaCl 1 g/L). M. 
xanthus DK1622 (ΔmchA) was propagated in CTT liquid medium (Casitone 10 
g/L, 1 M Tris pH 7.6 10 ml/L, 1 M K2HPO4 1 ml/L, 0.8 M MgSO4 10 ml/L, pH 
7.6) at 30 
o
C. Burkholderia sp. DSM7029 was cultivated in optimized CYCG 
medium (Casitone 6 g/L; Yeast extracts   2 g/L; Glycerol 0.5% v/v; CaCl2 × 
2H2O 1.4 g/L). P. putida KT2440 was grown in LB medium and the conjugants 
were selected in Pseudomonas minimum medium [74]. Appropriate antibiotics 
were added when needed (ampicillin, 100 μg/mL; kanamycin, 50 μg/mL; 
gentamicin, 5 μg/mL; tetracycline, 5 μg/mL; oxytetracycline, 5 μg/mL; 
chloramphenicol, 20 μg/mL; blasticidin, 40 μg/mL; zeocin, 25 μg/mL). Plasmid 
transformation and Red/ET recombination conditions are given in 
supplementary. 
Cloning and engineering of the vio gene cluster  
The genome of C. violaceus Cb vi35 was sequenced by Illumina Mseq 
sequencing. SuperCos 1 plasmid was used to construct the cosmid genomic 
library according to the manufacturer’s protocol. The vioprolide biosynthetic 
gene cluster (vio) was screened by colony hybridization. Several probes 
targeting on vioZ, vioD, orf3 and orf9 were generated by polymerase chain 
reaction (PCR) with the primer pairs ET21-cyclo-up / vio-5, Vio9-Cfor / Vio9-
Crev, vio-13 / vio-14 and vio-9 / vio-10. The positive clones were verified 
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further by Illumina Mseq sequencing. The missing parts of the gene cluster were 
obtained by PCR and Red/ET recombination. The procedures for construction of 
vio expression vector, repairing of the mutation sites, gene knock-out and site-
directed mutagenesis are shown in supplementary.  
Bioinformatics analysis 
    The vio gene cluster was annotated with antiSMASH platform [8, 9]. 
Domains and related ORFs in vio gene cluster were aligned with NCBI non-
redundant protein database by using the BLAST program 
(https://blast.ncbi.nlm.nih.gov). The specificity-conferring code of adenylation 
(A) domains was analyzed by NRPSpredictor2 web server 
(http://nrps.informatik.uni-tuebingen.de) and was compared with the selectivity-
conferring code table of A domains [69].  
Heterologous expression and analysis of vioprolides 
    M. xanthus mutants were fermented in 100 mL shaking flasks containing 25 
mL CTT medium with kanamycin and oxytetracycline and were cultivated for 
4.5 days at 30 
o
C on a rotary shaker (180rpm) , 0.7 mg/L pipecolic acid was 
added every 24 hours when necessary. B. sp. DSM7029 mutants were cultivated 
in 25 mL CYCG medium at 30 
o
C for 4.5 days, and P. putida mutants were 
fermented in 25 mL LB medium at 30 
o
C for 3 days. The absorber resin 
Amberlite XAD-16 (1%) was added 12 hours before compounds extraction. The 
XAD-16 resin was collected and compounds were extracted with methanol. The 
extracts were evaporated and dissolved in 1 mL methanol to make 25-fold 
concentrates, 1 μL concentrated extract was analyzed by high-performance 
liquid chromatography/electrospray ionization tandem mass spectrometry 
(HPLC-MS): a Thermo Scientific Dionex UltiMate 3000 Rapid Separation LC 
(RSLC) system coupled to amaZon speed ion trap mass spectrometer (Bruker 
Daltonics, Germany). Chromatographic separation was carried out on a Waters 
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Acquity UPLC BEH C18 column (50 × 2 mm, 1.7 μm particle size) with a 
solvent system consisting of ddH2O + 0.1% formic acid (A) and acetonitrile + 
0.1% formic acid (B) gradient at a flow rate of 0.6 mL/min and a temperature of 
45 
o
C. Gradient: 0-0.5 min 5% B; 0.5-9.5 min linear from 5%-95% B; 9.5-10.5 
min isocratic at 95% B; 10.5-11 min linear from 5% B. Vioprolides were 
identified by comparison to the retention time, molecular mass and MS/MS 
fragmentation patterns of the referential compounds (vioprolide A/B: m/z 
[M+H]
+
=863.4; vioprolide C/D: m/z [M+H]
+
=849.4). 
Construction of expression plasmids for in vitro assay 
    The FAAL-ACP-C-FkbH-PCP (FAAL-PCP) encoding sequence faal-pcp was 
amplified from p15A-Ptet-vio with Phusion DNA polymerase (Fermentas) by 
using primers Module1-NheI-5 and Module1-NotI-3, and was then cloned to 
pET28b-sumo-tev at Nhe I and Not I sites to generate pET28b-STFP. The faal-
pcp was also cloned to pET28b at Nco I and Not I sites to yield pET28b-FP 
which expresses FAAL-ACP with an N-terminal his-tag. The module 1 (FAAL-
ACP) expression vector pET28b-STFA was constructed by deleting c-fkbH-pcp 
on the plasmid pET28b-STFP. The 3’-terminal sequence of faal-acp was PCR-
amplified with primers FA-AatII-5 and FA-NotI3, and then replaced c-fkbH-pcp 
of the pET28b-STFP at Aat II and Not I sites. The encoding sequence of ACP 
domain (acp) was PCR-amplified with primers HisACP-NcoI5 and FA-NotI3, 
which was inserted into pET28b at Nco I and Not I sites to give pET28b-acp. 
The fkbH-pcp was amplified with primers KP-NheI5 and KP-NotI3, and was 
then cloned to pET28b-sumo-tev at Nhe I and Not I sites to generate pET28b-
STKP. The final expression vectors were verified by restriction enzymes and 
sequencing. 
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In vitro protein activity assay  
    Protein expression and purification procedures can be obtained in 
supplementary. Transformation of apo-FAAL-ACP and apo-ACP to their holo-
forms was performed by incubating 5 µM protein with 1 µM MtaA (PPTase), 8 
mM MgCl2 and 1 mM CoA at 37 
o
C for 1h. The fatty acid loading activity of 
FAAL-ACP was initially performed in 50 µL reaction system with 5 µM FAAL-
ACP, 1 µM MtaA (PPTase), 8 mM MgCl2, 1 mM CoA, 100 µM fatty acid (C16:0, 
iso-C16:0, C17:0 or iso-C17:0) and 5 mM ATP. The reaction mixture was incubated 
at 37 
o
C for 1h and measured with LC-MS (MaXis 4G). The in trans loading 
fatty acids to ACP was performed in two steps: internal palmitic acid in FAAL 
domain was transferred to its downstream ACP by incubation with 5 µM holo-
FAAL-ACP and 5 mM ATP at 30 
o
C for 30min. The final concentration of 10 
µM holo-ACP, 100 µM fatty acid (C16:0, iso-C16:0, C17:0 or iso-C17:0) and 5 mM 
ATP were then added to the reaction system and incubated at 30 
o
C for another 
30 min. 
The offloading of FAAL-PCP attached intermediates followed the reported 
procedure [28]. The apo-FAAL-ACP was initially loaded with fatty acid and 
glyceric acid. The reaction was performed in 100 µL reaction mixture with 6.5 
µM apo-FAAL-PCP, 1 µM MtaA, 0.625 U 3-phosphoglyceric phosphokinase 
(PGK, Sigma), 13 µM D-3-phosphoglyceric acid, 5 mM ATP, 100 µM fatty acid 
(C17:0 or iso-C17:0), 10 mM MgCl2 and 1 mM CoA. The reaction system was 
incubated at 30 
o
C for 1h. Cysteamine was then added to a final concentration of 
0.2 M and samples were stored at 4 °C overnight. The volume of all samples 
was adjusted to 500 µL with brine, prior to two rounds of extraction with 
ethylacetate. The combined ethylacetate phases were evaporated to dryness 
using an Eppendorf Concentrator plus (Hamburg, Germany). After 
reconstitution in 100 µL MeOH, samples were subjected to LC-FTICR-MS and 
–MS/MS characterization.  
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Measurement of intact proteins and protein-bound intermediates 
ESI-MS-measurements of intact proteins were performed on a Dionex 
(Germering, Germany) Ultimate 3000 RSLC system using a ProSwift RP-4H 
(monolithic PS-DVB), 250 × 1 mm column (Thermo, USA). Separation of 1 µL 
sample was achieved by a multistep gradient from (A) H2O + 0.1% formic acid 
+ 1% DMSO to (B) ACN + 0.1% formic acid + 1% DMSO at a flow rate of 200 
µL/min and 45 °C. Chromatographic conditions were as follows: 0-0.5 min, 5% 
B; 0.5-18.5 min, 5-65% B; 18.5-19.5 min, 65-98% B; 19.5-21.5 min, 98% B; 
21.5-23.5 min, 98-5% B; 23.5-26 min, 5% B. UV spectra were recorded by a 
DAD in the range from 200 to 600 nm. The LC flow was split to 75 µL/min 
before entering the maXis 4G hr-ToF mass spectrometer (Bruker Daltonics, 
Bremen, Germany) using the standard Bruker Apollo II ESI source. In the 
source region, the temperature was set to 180 °C, the capillary voltage was 4000 
V, the dry-gas flow was 6.0 L/min and the nebulizer was set to 1.1 bar. Mass 
spectra were acquired in positive ionization mode ranging from 600-1800 m/z at 
2.5 Hz scan rate. Protein masses were deconvoluted by using the Maximum 
Entropy algorithm (Copyright 1991-2004 Spectrum Square Associates, Inc.).  
The offloaded intermediates from FAAL-PCP were measured on a Dionex 
Ultimate 3000 RSLC system using a BEH C18, 100 × 2.1 mm, 1.7 µm dp 
column (Waters, Germany). Separation of 1 µL sample was achieved by a linear 
gradient from (A) H2O + 0.1% formic acid to (B) ACN + 0.1% formic acid at a 
flow rate of 600 µL/min and 45 °C. Gradient conditions were as follows: 
0-1 min, 5% B; 1-7 min, 5-95% B; 7-8.5 min, 95% B; 8.5-9 min, 95-5% B; 
9-11.5 min, 5% B.  UV spectra were recorded by a DAD in the range from 200 
to 600 nm. The LC flow was split to 75 µL/min before entering the solariX XR 
(7T) FT-ICR mass spectrometer (Bruker Daltonics, Germany) using the Apollo 
II ESI source. In the source region, the temperature was set to 200 °C, the 
capillary voltage was 4500 V, the dry-gas flow was 4.0 L/min and the nebulizer 
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was set to 1.1 bar. Mass spectra were acquired in positive ionization mode as 
reduced profile spectra ranging from 100-750 m/z with a FID data size of 1 M, a 
quadrupole accumulation time of 200 ms and data reduction set at 98%. Q-CID 
fragment spectra were recorded using a fragmentation voltage of 15 eV. 
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2.5 Supplementary 
Identification of previoprolides 
    C. violaceus Cb vi35 was cultivated in 20 mL fresh Cas medium (Bacto-
Casiton 10 g/L, MgSO4 × 7H2O 1 g/L, HEPES 10 g/L) in 100 mL flask at 30 
o
C 
for 3 days. Six milligrams isotope (L-Methionine-d3, L-Methionine-
13
C, L-
Methionine-
13
C5
15
N, L-Threonine-
13
C4
15
N or L-Proline-
13
C5
15
N) was added in 
four portions to the culture at the time point of 0, 72, 96, 120 h after inoculation. 
C. violaceus Cb vi35 fermented without feeding was set as negative control. 
After fermentation XAD-16 absorber resin (1%) was added and incubated with 
the culture overnight. Compounds were extracted with methanol (1:1), 
evaporated and re-dissolved in 500 μL methanol, and 1 µL crude extract was 
analyzed by UPLC-HRMS. 
 
Fig. S1 Identification of previoprolides from C. violaceus Cb vi35. UPLC-
HRMS profiles of the compounds from cell medium (supernatant) and cell pellet 
are shown separately. EIC m/z of vioprolides (green) and previoprolides (red) 
are shown. Intensity is adjusted to the same range. 
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Fig. S2 HPLC-MS analysis of isotopically labeled previoprolides in C. violaceus 
Cb vi35. (A) HPLC profile of the previoprolides, the base peak (BPC) m/z 1000-
1500 is shown; (B) mass spectra of previoprolides. The number of labeled 
methionine and theronine is shown in red arrows. 
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Fig. S3 Identification of previoprolides in M. xanthus::Ptet-vio. UPLC-HRMS 
profiles of the compounds from cell medium (supernatant) and cell pellet are 
shown separately. EIC m/z of vioprolides (green) and previoprolides (red) are 
shown. Intensity is adjusted to the same range. 
 
Fig. S4 Identification of previoprolide in Burkholderia sp.DSM7029::Ptet-vio. 
HPLC profiles of the compounds from cell medium (supernatant) and cell pellet 
are shown separately. Most of the vioprolide B (indicated with dashed box) was 
secreted into cell medium, whereas previoprolide was intercepted in bacterial 
cells. EIC m/z of vioprolides (green) and previoprolides (red) are shown. 
Intensity is adjusted to the same range. 
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Characterization of vioprolide biosynthetic gene cluster 
Table S1 Proposed function of the genes in the scaffold000098 
Gene  Size (aa) Proposed Function * Identity Accession No.  
orf2  328 Hypothetical protein  36% CRM73716.1 
orf1 437 Transposase  58% WP_014399689.1 
vioZ 378 Ornithine cyclodeaminase 60% WP_013376531.1 
vioA 4913 NRPS: FAAL (23-570), ACP (596-
677), C (705-1001), FkbH (1363-
1680), PCP (1782-1848), E (1865-
2167), C (2336-2634), A (2804-
3284), PCP (3298-3369), C (3392-
3690), A (3868-4342), PCP (4363-
4423), E (4441-4742) 
44% WP_050045606.1 
vioB 2159 NRPS: C (4-306), A (478-974), PCP 
(998-1061), Cy (1098-1396), A 
(1573-2053), PCP (2075-2139) 
45% WP_006635040.1 
vioC 3320 NRPS: C (85-381), A (556-1043), 
PCP (1068-1129), C (1160-1459), A 
(1627-2113), PCP (2136-2200), C 
(2221-2526), A (2699-3191), PCP 
(3214-3275) 
50% KYC42747.1 
vioD 1795 NRPS: C (43-343), A (515-951), 
NMT (1010-1131), PCP (1439-
1502), TE (1524-1778) 
46% WP_002733092.1 
orf3  600 Unusual protein kinase 32% WP_006512948.1 
orf4 443 Hypothetical protein Y590_21885  35% AMB47606.1 
orf5 550 Biotin synthase 1 56% KKS93718.1 
orf6 237 SAM-dependent methyltransferase 31% WP_066486480.1 
orf7 96 Hypothetical protein 40% WP_040137362.1 
orf8 96 Hypothetical protein 38% WP_024750041.1 
orf9 70 Antibiotic synthesis protein MbtH 89% WP_043389803.1 
orf10 362 GphU 98% AHA38214.1 
orf11 118 Response regulator 99% WP_043408217.1 
orf12 546 Molecular chaperone GroEL 99% WP_043408220.1 
orf13 518 Chemotaxis protein CheY 97% WP_043408223.1 
orf14 131 Ferritin 100% WP_043408226.1 
orf15 458 Diguanylate cyclase response 
regulator 
99% 
WP_043408229.1 
orf16 257 Hypothetical protein 98% WP_043408232.1 
*  Positions of NRPS domains are indicated in brackets; FAAL, fatty acyl-AMP 
ligase; ACP, acyl-carrier-protein domain; C, condensation domain; PCP, 
peptidyl-carrier-protein domain; E, epimerase; A, adenylation domain; Cy, 
heterocyclization domain; NMT, N-methyltransferase; TE, thioesterase. 
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Table S2 Specificity-conferring codes of the A domains in vioprolide NRPSs 
A domains 
Active residues (position) 
235 236 239 278 299 301 322 330 331 517 
A1: Ala D V W H L S L I E K 
A2: Leu D A W F L G H V V K 
A3: AZE/Pro D V Q C L S E V T K 
A4: Cys D L Y N L S L I W K 
A5: Dhb (Thr) D F W N I G M V H K 
A6: Pip/Pro D I Q Y Y A Q V V K 
A7: Thr D F W N I G M V H K 
A8: Val D A F W L G G T F K 
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Sequence analysis of C domains 
 
C domain Motif C1 Motif C2 Motif C3 
Vio-C1 LPLSRHQLRLWWLE ARYQLHLALRLEGDLQAHLLVRALELLVERHEALRATFS VHHLVADGLSLEILVRELVASY 
Vio-C2 YPLAPVQQGMLFHT GVYLEQWRARLRGPLDARALRAALEGIIERHASLRTAFQ LHHLLLDAWSGLLVFREFITLY 
Vio-C3 PPVSFAQQRLWFLH HAYHVVHALRLSGRLDTGAFERGLEEVVRRHETLRTTFR MHHIISDGWSMGVLVRELAELY 
Vio-C4 YPLTPMQQGMLYHS EVYFEQMCCSLRGRLVPAVLERAWQEVVNRHPALRTAFL HHHLLLDGWSLPRLLKEVFTCY 
Vio-C6 LAASFAQQRLWLVD PAYNLAFGIRMTGPVDAVALEEALNECVRRHEALRTRFT MHHIVSDGWSLGVLAWELLTLY 
Vio-C7 YPLSMLQGGMVFHG AIYHDIFSFHVRAPFEPEAWRGAVSELLRHHPVLRTSIE FHHVILDGWSNAMMLTELNQRY 
Vio-C8 LPLSFGQQRLWFLE AAYHMFVPLRADGVLEPVLLKRCLEALVRRHESLRTTFV LHHIIADGWSLGVLVRELAALY 
Vio-C9 VPLSFAQRRLWFLH AAYHMTYALRLSGELRVGALEASFAAIVQRHEALRTGFS MHHIVSDGWSMGVIVRELVALY 
 
C 
domain 
Motif C4 Motif C5 Motif C6+C7 
Vio-C1 SYAEALRLIDAHA DLVVGVPLQGRRHSALVPQVGFFASPLVLR RAGLLDGWARQDVPLNRLIELARVDRGAPWHPLFQVMFSV 
Vio-C2 PYRDYIAWLRARE DLVLGLTVSGRPAELPGVESMVGLFVNSLPLR QERQAQLQGYQYTPLVDIQGWSEVPRGTSLFETLFAFE 
Vio-C3 QYADHAIWQRKKS DIIVGTPIANRNRAELEPLIGFFVNTLALR RAVALDAYVHQDVPFERVVEALQPTRDLSRSPIFQVVCAM 
Vio-C4 PFREYIGWLQAQP DVLFGVTVSGRPPQLPGVESMIGLFINTLPLR QEQQAELRQYEHTPLVRIHGWSDVPREQPLFSSIVVFENYV 
Vio-C6 QYADFTAWQRERL DIAVSTPVANRPARELEGLIGFFVNTLVLR RSGVAEDFAHQEMPFEQLVEALHQERDLGRQPLSQVMFVL 
Vio-C7 AFRDFVALERSAL EVVTGLVANGRPESTDAARSLGLFLNTLPLR FAAEQELMPHRWFPMAEVRRLLGGVPLFEVGFNFVH 
Vio-C8 QYADFALWQRREL DILIGSPIAHRTRSELEELIGFFVNTQVLR REVSLGAHAHQHLPFERLVERLQPERDPSRTPLFQVVFVM 
Vio-C9 QYADFAVWQRQWL DLVVGSPVANRHHRE--LENLIGFFVNTLCLR RDAAMGAYAHQDLPFERIVEALQPERDASRNPLVQVMFAL 
Fig. S5 Core motif analyses of C domains in vioprolide NRPSs. The crucial 
residues of 
D
CL domains are illustrated in red, and other characteristic residues 
are labeled in yellow. Comparing to the conserved residues reported by Rausch 
[1],  C2, C4 and C7 seem to be 
D
CL domain while others are 
L
CL domain.  
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Fig. S6 Phylogenetic analysis of ester bond forming C domains and the C 
domains in vioprolide NRPSs. Phylogenetic tree was generated by FastTree 
plugin in Geneious R9. The C, E and Cy domains in vioprolide NRPS are 
marked with blue dots, vioprolide C1 domain is labled with red dot and other 
ester bond forming C domains are indicated with green dots. 
L
CL, C domain 
condensates L-donor and L-acceptor; 
D
CL, C domain condensates D-donor and L-
acceptor; Dual, C domain with both condensation and epimerization functions; 
Cy, cyclization domain; Epi, epimerization domain; Starter, starting C domain. 
Evolutionary distance is shown in scale bar. 
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In vitro experiments 
The expression vector pET28b-STFP, pET28b-FP and pET28b-STFA (Fig. 
S8) were transformed into E. coli Rosetta (DE3), and pET28b-ACP and 
pET28b-STKP were transformed into E. coli BL21 (DE3). The transformants 
were selected on LB-agar plates with kanamycin. The recombinant protein 
expressing strains were cultivated in LB liquid medium at 37 
o
C overnight. The 
overnight culture (1% v/v) of E. coli Rosetta (DE3)::pET28b-STFP, E. coli 
Rosetta (DE3)::pET28b-FP, E. coli BL21 (DE3)::pET28b-ACP or E. coli BL21 
(DE3)::pET28b-STKP was then inoculated to 4 × 1.5 L LB. IPTG in an final 
concentration of 0.1 mM was added when OD600 reached up to 0.6. Cells were 
grown at 16 
o
C for an additional 20 hours before collection. The E. coli Rosetta 
(DE3)::pET28b-STFA was inoculated to 4 × 1.5 L ZYM5052 auto-induction 
medium and cultivated at 37 
o
C for 4 hours before growing at 16 
o
C for 20 hours. 
The overnight culture (2% v/v) of MtaA expressing strain BL21 (DE3)::pCold-
MtaA+pGro7 (a gift from Dr. Hilda Sucipto) was inoculated into 1 L LB broth 
with supplement of 2 mg/mL L-Arabinose, cells were cultivated at 37 
o
C until 
OD600 reached up to 0.6. The cells were induced with 0.1 mM IPTG and allowed 
to grow at 16 
o
C overnight. 
Cells were harvested by centrifugation (8000 rpm, 10min, 4 
o
C) and 
suspended in 100 mL washing buffer ([50 mM HEPES, 300 mM NaCl, 20 mM 
imidazole, pH 8.0] for FAAL-PCP, FAAL-ACP, ACP and FkbH; [20 mM Bis-
Tris pH 6.8, 200 mM NaCl, 20 mM imidazole,  10% glycerol] for MtaA), and 
then disrupted by M-110P Microfluidizer® (Microfluidics). A proteinase 
inhibitor cocktail tablet (cOmplete™, Mini, EDTA-free Protease Inhibitor 
Cocktail, Roch) and 1 mg DNAse I (Roch) were added before cell disruption. 
Lysate was clarified by high speed centrifugation (20000 rpm, 30 min, 4 
o
C) and 
the supernatant was loaded to HisTrap HP 5 mL column (GE Healthcare) 
connected with the HPLC system (ÄKTA avant 25, GE healthcare). After 
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washing with 10 CV (column volume) washing buffer, the recombinant protein 
was eluted with gradient elution buffer ([50 mM HEPES, 300 mM NaCl, 250 
mM imidazole, pH 8.0] for FAAL-PCP, FAAL-ACP, ACP and FkbH; [20 mM 
Bis-Tris pH 6.8, 200 mM NaCl, 250 mM imidazole,  10% glycerol] for MtaA) 
by increasing concentration of imidazole. Recombinant proteins were desalted 
and the buffer was exchanged ([10 mM Tris, 200 mM NaCl, pH 8.0] for FAAL-
PCP, FAAL-ACP, ACP and FkbH; [20 mM Bis-Tris pH 6.8, 200 mM NaCl, 10% 
glycerol] for MtaA) by HiPrep 26/10 Desalting column connected to HPLC 
system (ÄKTA pure, GE Healthcare). When SUMO-tag needs to be cut off, 
recombinant protein was incubated with 10% (w/w) TEV protease at 4 
o
C 
overnight. Afterwards, the SUMO-free protein was incubated with 1 mL Ni-
NTA Agarose (Qiagen) at 4 
o
C for 1 h. The protein-resin mixture was then 
loaded to Ni-NTA Superflow Column (1.5 mL, Qiagen) and the gravity flow 
through containing tag-free protein was collected. The desalted or SUMO-free 
protein was purified further on Superdex 200 Increase 10/300 GL gel filtration 
column (for FAAL-ACP, ACP and FkbH) or HiLoad 16/600 Superdex 200 pg 
gel filtration column (for FAAL-PCP and MtaA) with the aid of HPLC system 
(ÄKTA pure). The purified proteins were concentrated with Amicon® Ultra 
centrifugal filter (Millipore), supplemented with 10% glycerol, snap frozen in 
liquid nitrogen and stored at -80 
o
C. The purified proteins were checked by 
SDS-PAGE (Fig. S9). 
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Fig. S8 The maps of protein expression vectors and the resulting domains. 
FAAL contained an inherent palmitoyl-AMP, whereas glycerate was loaded to 
PCP in E. coli. 
 
 
Fig. S9 SDS-PAGE analysis of the purified proteins. The fractions from gel 
filtration were checked by SDS-PAGE. The sizes of the purified proteins are 
illustrated. M, protein molecular weight (Fermentas). 
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Fig. S10 Biochemical characterization of the module 1. LC-MS analysis of the 
fatty acid bound FAAL-ACPs. (A) fatty acids (C16:0, iso-C16:0, C17:0 or iso-C17:0) 
incubated with apo-FAAL-ACP were served as negative control; (B) fatty acids 
incubated with holo-FAAL-ACP. Only C16 was attached to holo-FAAL-ACP no 
matter what kind of fatty acid was added in the the reaction. 
 
Plasmid transformation and Red/ET recombination conditions 
    For the routine transformation of E. coli, 1 mL cells (OD600≈0.6) were washed 
twice with 1 mL ddH2O and were suspended in 50 μL ddH2O, 500 ng DNA was 
mixed well with cells in 1 mm cuvette and electroporated in the Eppendorf 
Eporator® at 1300 V. Transformants were recovered in 1 mL LB at 37 
o
C for 1 
hour and were selected on LB-agar plates with appropriate antibiotics. To 
perform linear plus circular homologous recombination (LCHR) [2], 40 μL 
overnight culture of recombineering strain (E. coli GB05-red or GBred-gyrA462 
harboring corresponding constructs) was inoculated in 1.6 mL fresh LB broth 
until OD600 reached up to 0.3, 50 μL 10% arabinose was then added to the 
culture to induce the expression of recombinase, and cells were allowed to grow 
at 37 
o
C for another 45 min before preparing of electro-competent cells. 
Electroporation of appropriate inserts into recombinase proficient cells was 
carried out as routine transformation.  
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For the transformation of myxobacteria, M. xanthus DK1622 (∆mchA) was 
inoculated in CTT medium and cultivated at 30 
o
C for 2 days, 1.5 mL cultures 
was then transferred into 12 mL fresh medium and was allowed to grow at 30 
o
C 
overnight. Cells were washed twice with cold ddH2O and suspended in 50 μL 
ddH2O before being mixed with 2 μg plasmids and electroporated at 1300V. 
Cells were recovered in 1.6 mL CTT medium at 30 
o
C for 6 hours. The 
recovered cells were mixed with 10 mL 0.7% soft agar (with appropriate 
antibiotics) and plated on CTT-agar plates with kanamycin and oxytetracycline. 
Plates were incubated at 30 
o
C until single colonies appeared. For the 
transformation of Burkholderia sp. DSM 7029, 1.6 mL cells (OD600 ≈ 0.8) was 
washed twice with 1.6 mL cold ddH2O and suspended in 50 μL ddH2O, 500 ng 
plasmids was mixed with cells in 1 mm cuvette and electroporation was carried 
out at 1300V. After recovery in 1.6 mL CYCG medium at 30 
o
C for 3 hours, 
transformants were selected on CYCG-agar plates with kanamycin. Plasmid 
transfer from E. coli GB05-red to P. putida KT2440 was performed by 
conjugation with the help of pRK2013 as previously reported [3]. 
 
Cloning and engineering of the vio gene cluster  
    The flowchart of vioprolide expression vector construction is displayed in Fig. 
S11. The cosmid EK21 (a) containing most part of the vio gene cluster was used 
for further engineering. The missing part of vioZ was amplified from the 
genomic DNA of C. violaceus Cb vi35 by using primers V-overlap-5 and vio-5, 
zeocin resistance gene zeoR was amplified with primers V-zeo and V-overlap3, 
an Nhe I restriction site was introduced in the 5’-terminus. Overlap extension 
PCR was used to ligate zeoR and vioZ by using primers V-overlap-5 and V-
overlap3. The zeoR-vioZ cassette (b) was inserted into pUC-cosmid EK21 (a) by 
Red/ET recombination. Hereafter ampicillin resistance gene ampR (c) was 
amplified by primers V-amp-5 and V-amp-3, which replaced the neoR 
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(neomycin resistance gene) downstream of vioD by Red/ET recombination to 
generate pUC-ampR-zeoR-vioZ-cosmid EK21 (d), another Nhe I restriction site 
was introduced in front of ampR simultaneously. Direct cloning was used to 
clone the missing genes downstream of vioD, p15A-Tn5-kmR linear fragment 
(Tn5, Ptn5 promoter; IR, inverted repeat; kmR, kanamycin resistance gene) with 
homologs of vioD and orf9 was amplified by using primers vioD-15A and vioD-
neo. Here, an Avr II restriction site was introduced in the primer vioD-15A. The 
p15A-Tn5-kmR linear fragment and BsrD I digested Cb vi35 genomic DNA 
were co-transformed into recombinase proficient E. coli GB05-red, the p15A-
Tn5-kmR-vioD-orf9 (e) carring the vioD~orf9 was then obtained by Red/ET 
recombination.   
To stitch the vio gene cluster, the (d) and the (e) were digested with Nhe I and 
Avr II, respectively. The vioZ-cosmid EK21 fragment harboring vioZ~vioC was 
ligated with vioD to obtain p15A-Tn5-kmR-zeoR-vio (f). The IR-Tps-BSD-oriT 
cassette (g) (Tps, MycoMar transposase gene; BSD, blasticidin resistance gene) 
[4] was then amplified by using primers Vio-Tps5 and P15AUpSeq, and was 
integrated into the backbone of (h) by Red/ET recombination. Thereafter, gentR-
tetR-Ptet cassette (i) was used to replace the zeoR in (h) to generate p15A-Tps-
BSD-oriT-Tn5-kmR-gentR-tetR-Ptet-vio (j). The (j) was sequenced and aligned 
with Cb vi35 genome data. However, several mutation sites were discovered in 
vioA, vioD and vioZ. 
Mutation sites in the vio gene cluster were repaired by ccdB counter selection 
as previously reported [5]. In order to repair the mutation site in vioD, 
vioDampR-ccdB cassette (k) was amplified from p15A-ccdB-amp and 
transformed into recombineering competent E. coli GBred-gyrA462 harboring 
(j), recombinants (l) were selected on LB-agar plates with kanamycin and 
ampicillin. The vioD-3term fragment containing 201 bp 3’-terminus of vioC was 
amplified from Cb vi35 genome by using primers vioCDlig15 and vioCDlig13, 
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and the vioD5term fragment contains 204 bp 5’-termini of vioD was amplified 
from the genome by using the primers vioCDlig25 and vioCDlig23. The vioC-
3term and the vioD5term were ligated by overlap extension PCR to obtain 
vioCDlig (m), 500 ng (m) was transformed into recombineering proficient E. 
coli GBred-gyrA462 harboring (l) to replace the ampR-ccdB cassette, cells were 
recovered in 1.6 mL LB medium for 3 hours, the plasmids were then extracted 
by alkaline lysis and retransformed into E. coli GB05-red, E. coli GB05-red 
harboring p15A-Tps-BSD-oriT-Tn5-kmR-gentR-tetR-Ptet-violig (n) were 
selected on LB-agar plates supplemented with kanamycin. Recombinants were 
checked by restriction enzymes and sequencing.  
To repair the mutation site in vioA, vioAcmR-ccdB cassette (o) was amplified 
from p15A-ccdB-Cm by using primers XmaJIhomolog-cm5 and Homolog-
cmccdB3, and was transformed into recombineering proficient E. coli GBred-
gyrA462 in which (n) was resident. Recombinants (p) were selected on LB-agar 
plates with kanamycin and chloramphenicol. The 466 bp vioAseq2 (q) with 
corrected mutation site of vioA was amplified from the genome of C. violaceus 
Cb vi35 by using primers vioAseq5 and vioAseq32. After transforming 500 ng 
(q) into recombinase induced E. coli GBred-gyrA462 harboring (p), cmR-ccdB 
cassette was removed and plasmids were transformed into E. coli GB05-red. E. 
coli GB05-red carring the vioprolide expression construct p15A-Ptet-vioArecov-
vio (r) was selected on LB-agar plate with kanamycin. Recombinants were 
analyzed by Pvu II and verified further by Sanger-sequencing (Fig. S12). 
To repair the mutation site in vioZ, the primers Ptetviozcmccdb5 and 
Ptetviozcmccdb3 were used to amplify vioZcmR-ccdB (s) from p15A-ccdB-Cm. 
The PCR product was transformed into recombinase proficient E. coli GBred-
gyrA462 harboring (r) and was inserted between Ptet promoter and vioZ to 
generate (t) by Red/ET recombination. Correct 3’-terminus of vioZ (u) was 
amplified from the genome of C. violaceus Cb vi35 by using the primers 
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Ptetviozrecov5 and vioZrecov3, which then replaced the cmR-ccdB cassette to 
obtain (v). In this way, the Ptet promoter was retained to drive the whole gene 
cluster. In order to change the Ptet promoter to Ptn5 promoter, vioZampR-ccdB 
cassette (w) was amplified from p15A-ccdB-amp by using the primers 
vioZampccdB5 and vioZampcounter3. The PCR product was transformed into 
recombinase proficient E. coli GBred-gyrA462 harboring (r) to replace the 
gentR-tetR-Ptet cassette.  Correct 5’-terminus of vioZ (y) was amplified from the 
genome of C. violaceus Cb vi35 by using primers vioZrecov5 and vioZrecov3, 
and substituted the ampR-ccdB cassette via Red/ET recombination to generate 
(z). In this case, vioZ was co-transcripted with kmR and was controlled by Ptn5 
promoter. The vioprolide final expression vectors p15A-Ptet-vio (v) and p15A-
Tn5-vio (z) were verified by restriction digestions and Sanger-sequencing (Fig. 
S13). 
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Fig. S11 Engineering of vio gene cluster for heterologous expression. The vio 
gene cluster was cloned from cosmid library and was constructed to expression 
vector by conventional cloning (a-f); elements for transcription and transposition 
were added to expression vector (g-i); several mutation sites were repaired by 
ccdB counter selections (j-z). *, mutation sites discovered in the vio gene cluster. 
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Fig. S12 Repair of the mutation site in vioA. The mutation site in vioA is 
indicated with a red box (A). The repaired site was verified by Sanger-
sequencing (B) and Pvu II digestion (C). The correct clones are indicated with 
white stars. NC, negative control (p15A-Tps-BSD-oriT-Tn5-Km-gentR-Ptet-
vioAcmccdB-violig); PC, positive control (p15A-Tps-BSD-oriT-Tn5-Km-
gentR-Ptet-violig); M, 1kb DNA ladder. 
 
Fig. S13 Identification and repair of the missing part in vioZ. The missing part 
of vioZ was identified by comparing the DNA sequence with the genome 
sequence of C. violaceus Cb vi35 (A) or by alignment of the protein sequence 
with other cyclodeaminase-like proteins (B); the repaired vioZ was verified by 
Sanger-sequencing (C). The missing part of vioZ is indicated with red box; the 
repaird part is indicated with blue box. 
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Fig. S14 LC-HRMS analysis of vioprolide production in P. putida KT2440. 
Extracted ion chromatogram (EIC) m/z for 849.4 [M+H]
+
 (vioprolide D) and 
863.4 [M+H]
+
 (vioprolide B and isomer) is shown. Intensity is set to the same 
range. 
 
 
Generation of ∆orf3-∆orf9 mutants  
The genes orf3-orf9 in the downstream of vioD were deleted by Red/ET 
recombination. The flow chart is shown in Fig. S15. Nine pairs of primers 
(orf3Del-cm5 / orf3Del-cm3, orf4Del-cm5 / orf4Del-cm3, orf5Del-cm5 / 
orf5Del-cm3, orf6Del-cm5 / orf6Del-cm3, orf5Del-cm5 / orf6Del-cm3, orf7Del-
cm5 / orf7Del-cm3, orf8Del-cm5 / orf8Del-cm3, orf9Del-cm5 / orf9Del-cm3, 
and orf3Del-cm5 / orf9Del-cm3,) containing the respective homologs of orf3 to 
orf9 were used to amplify cmR from p15A-ccdB-Cm. XmaJ I restriction sites 
were designed in the primers. The resulting inserts orf3Delcm, orf4Delcm, 
orf5Delcm, orf6Delcm, orf5-6Delcm, orf7Delcm, orf8Delcm, orf9Delcm and 
orf3-9Delcm were transformed into recombinase proficient E. coli 
GBred::p15A-Ptet-vioArecov-vio, and the orf3, orf4, orf5, orf6, orf5&6, orf7, 
orf8, orf9 or orf3-9 on p15A-Ptet-vioArecov-vio was replaced by cmR via 
Red/ET recombination, respectively. The resulting p15A-Ptet-vioArecov-vio-
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orfNDelcmR (N=3, 4, 5, 6, 5&6, 7, 8, 9 or 3-9) was digested with XmaJ I to 
remove the cmR, and the linear construct was self-ligated by T4 DNA ligase. 
The mutants, designated p15A-Ptet-vioArecov-vio-orfNDel (N=3, 4, 5, 6, 5&6, 
7, 8, 9 or 3-9), were checked by Bsp119 I and XmaJ I (Fig. S16), and were 
transformed into M. xanthus DK1622 (∆mchA) and Burkholderia DSM 7029. 
The transformants were checked by colony PCR (Fig. S17). The M. xanthus 
transformants were fermented in CTT medium, whereas Burkholderia 
transformants were fermented in CYCG medium. Compounds were extracted 
with XAD16 and methanol. The production of vioprolides was measured with 
LC-MS (Fig. S18). 
 
Fig. S15. Flow chart for the construction of ∆orf3-∆orf9 mutants. The orfN 
(N=3, 4, 5, 6, 5&6, 7, 8, 9 or 3-9) was initially replaced by cmR via Red/ET 
recombination, the resulting constructs were then digested with XmaJ I to 
remove cmR and were self-ligated with T4 DNA ligase.  
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Fig. S16 Restriction analyses of ∆orf3-∆orf9 mutants. The mutants p15A-Ptet-
vioArecov-vio-orfNDel (N=3, 4, 5, 6, 5&6, 7, 8, 9 or 3-9) were checked with 
Bsp119 I and XmaJ I; p15A-Ptet-vioArecov-vio-orfNDelcm (NC3-NC9) and 
p15A-Ptet-vioArecov-vio (NC) were set as negative control; M, 1kb DNA 
ladder. 
 
Fig. S17 Colony PCR analyses of ∆orf3-∆orf9 transformants. NC, M. xanthus 
DK1622; PC1, p15A-Ptet-vioArecov-vio; PC2, M. xanthus::Ptet-vioArecov-vio; 
V3-V9, plasmid control, p15A-Ptet-vioArecov-vio-orfNDel (N=3, 4, 5, 6, 5&6, 
7, 8, 9 and 3-9, respectively); T1-T3, M. xanthus transformants; M, 1kb DNA 
ladder. 
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Fig. S18 HPLC-MS analyses of vioprolides in ∆orf3-∆orf9 mutants. (A) 
production of vioprolides in M. xanthus DK1622 (ΔmchA) transformants; (B) 
production of vioprolides in Burkholderia sp. DSM7029 transformants. 
Extracted ion chromatograms (EIC) m/z for 849.4 [M+H]
+
 (vioprolide Dand 
isomer) and 863.4 [M+H]
+
 (vioprolide B and isomer) are shown. The produced 
vioprolides are indicated with shadowed boxes. Intensity is adjusted to the same 
range. 
 
Site-directed mutagenesis on A1 and NMT domain 
    Site-directed mutagenesis was performed by ccdB counter selection. To 
mutate the position 331 (Glu) of the A1 domain into Asp and the conservative 
Gly of the NMT domain into Arg, the cmR-ccdB cassette with homologs of A1 
domain and NMT domain were amplified from p15A-ccdB-Cm by using primer 
pairs VioA1mutcmccdB5 / VioA1mutcmccdB3 and NMTmutcmccdB5 / 
NMTmutcmccdB3, respectively. The PCR products VioA1mutcmccdB or 
NMTmutcmccdB was transformed into recombinase proficient E. coli GBred-
gyrA462::p15A-Ptet-vioArecov-vio, and the target region of A1 or NMT domain 
were replaced by cmR-ccdB, respectively. The recombinants were selected on 
LB-agar plates with kanamycin and chloramphenicol. The site-mutated 
fragments VioA1E-D and NMT-G-R were amplified from p15A-Ptet-vioArecov-
vio by using primer pairs VioA1E-D5 / VioA1E-D3 and NMT-G-R-5 / NMT-G-
R-3, and were transformed into recombinase proficient E. coli GBred-
gyrA462::p15A-Ptet-vioArecov-vioA1mutcmccdB and E. coli GBred-
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gyrA462::p15A-Ptet-vioArecov-NMTmutcmccdB, respectively. The resulting 
recombinants were designated p15A-Ptet-vioArecov-A1E331D and p15A-Ptet-
vioArecov-NMTmut, respectively. The A1 domain and NMT domain double 
mutation was generated by introducing A1E331D mutation in p15A-Ptet-
vioArecov-NMTmut in the same way. All clones were verified by restriction 
analysis and Sanger-sequencing (Fig. S19). 
 
Fig. S19 Anaysis of the site-directed mutagenesis on AAla domain and NMT 
domain. Mutants were checked by Bsp119 I and XmaJ I (A) and Sanger-
sequencing (B). The correct clones are indicated with white stars; the position 
331 of the A1 domain and the crucial Gly in the NMT domain are illustrated; the 
mutated positions are labeled with red boxes. 
 
Purification of vioprolide derivatives and structure elucidation 
M. xanthus::Ptet-vioArecov-vio or M. xanthus::Ptet-vioArecov-vioA1mut was 
cultivated in 5 × 2 L CTT medium at 30 
o
C for 4.5 days, 33.4 mg/L pipecolic 
acid was added every 24 hours, 1% Ambliter XAD-16 resin was added after 4 
2. Manuscript 
 
97 
 
days and was incubated with cultures overnight. Compounds were extracted 
with methanol and the solvent was evaporated with a vacuum system. The dried 
substance was extracted with ethyl acetate : ddH2O (2 : 1) and was concentrated 
by evaporation. The derivatives were separated with Sephadex LH-20 column 
(GE Healthcare) using methanol as mobile phase. Fractions were collected with 
a sample collector. Fractions containing vioprolide derivatives were purified 
further by HPLC. 
    Purification of vioprolides was carried out on a Dionex (Germering, Germany) 
Ultimate 3000 low pressure gradient system, equipped with SR3000 solvent 
rack, LPG-3400SD pump module, WPS-3000TSL autosampler, Knauer (Berlin, 
Germany) Jetstream column oven and a DAD-3000 photodiode array detector 
with a cell volume of 10 µL. Cleanup was carried out using 100 µL injections of 
sephadex fractions reconstituted in 250-400 µL MeOH on a Phenomenex Luna 
C18(2) HPLC column (250 × 10 mm, 4 µm). The gradient conditions were as 
follows: 0-52 min, 5-80% B; 52-52.5 min, 80-95% B; 52.5-56 min, 95% B; 
56-56.5 min, 95-5% B; 56.5-66.5 min, 5% B. Mobile phases were (A) water and 
(B) methanol. The separation was carried out with a column temperature of 
40 °C at a flow rate of 5 mL/min. Fractions were collected using an AFC-3000 
fraction collector based on retention time. Impure fractions were further purified 
using 100 µL injections of LC fractions reconstituted in 350-1000 µL MeOH on 
an Agilent Zorbax XDB C8 HPLC column (9.4 × 250 mm, 5 µm). The 
following gradient conditions were used: 0-40 min, 30-85% B; 40-40.1 min, 
85-95% B; 40.1-42.1 min, 95% B; 42.1-42.3 min, 95-30% B; 42.3-52 min, 
30% B. Mobile phases were (A) water and (B) methanol. The separation was 
carried out with a column temperature of 40 °C at a flow rate of 5 mL/min. 
Fractions were collected using an AFC-3000 fraction collector based on 
retention time. 
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Purification of hydroxyl-vioprolides was carried out on a Dionex (Germering, 
Germany) Ultimate 3000 low pressure gradient system, equipped with SR3000 
solvent rack, LPG-3400SD pump module, WPS-3000TSL autosampler, Knauer 
(Berlin, Germany) Jetstream column oven and a DAD-3000 photodiode array 
detector with a cell volume of 10 µL. LC separations were performed using 100 
µL injections on a Agilent Zorbax XDB C8 HPLC column (9.4 × 250 mm, 5 µm) 
at 40°C and a flow rate of 5 mL/min with the following gradient conditions: 
0-40 min, 10-65 %B; 40-40.1 min, 65-95% B; 40.1-44.1 min, 95% B; 
44.1-44.3 min, 95-10% B; 44.3-54 min, 10% B. Mobile phases were (A) water 
and (B) methanol. 
For the purification of previoprolides, initial cleanup was carried out by using 
500 μL injections of methanolic cell extract on a Phenomomenex Kinetex 
Biphenyl HPLC column (10 × 250 mm, 5 μm). A linear gradient with the 
following conditions was used: 0-20 min, 5-95%B; 20-22 min, 95%B; 22-22.5 
min, 95-5% B; 22.5-28.5 min, 5% B. Mobile phases were (A) water and (B) 
acetonitrile. The separation was carried out with a column temperature of 40 °C 
at a flow rate of 7 mL/min. And the final purification step was carried out by 
using 500 μL injections of crude fractions reconstituted in 6 mL methanol on an 
Agilent Zorbax XDB C8 HPLC column (9.4 × 250 mm, 5 μm). A linear gradient 
with the following conditions was used: 0-7 min, 5-75% B; 7-35 min, 75-95% B; 
35-38 min, 95% B; 38-38.5 min, 95-5% B; 38.5-47 min, 5% B. Mobile phases 
were (A) water and (B) acetonitrile. The separation was carried out with a 
column temperature of 40 °C at a flow rate of 7 mL/min. Fractions were 
collected using an AFC-3000 fraction collector based on retention time. 
Structures of the purified vioprolides and vioprolide D1 were assigned with 
NMR (Table S3). The NMR spectra of the vioprolide derivatives were recorded 
in methanol-d4 on a Bruker Avance III 500 NMR spectrometer (Bruker 
Karlsruhe, Germany) with a 5 mm TCI cryoprobe (
1
H at 500 MHz, 
13
C at 125 
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MHz) or a Bruker Ascend 700 spectrometer with a 5 mm TXI cryoprobe (
1
H at 
700 MHz, 
13
C at 175 MHz). Chemical shifts were calibrated internally to the 
residual signal of methanol-d4 in which the sample was dissolved (δH 3.31, δC 
49.15). 
 
Table S3 NMR spectroscopic data of vioprolide D, vioprolide D isomer and 
vioprolide D1 
 
vioprolide D 
vioprolide D 
(isomer) 
vioprolide D1 
    δC δH δC δH δC δH 
N-
methylvaline 
1 171,6 
 
170,9 
 
171,8 
 
2 67,3 4,08 66,7 4,53 67,8 4,13 
3 28,7 2,34 29,3 2,32 28,7 2,37 
4 20,7 1,01 19,9 1,07 20,7 1,04 
5 19,7 0,90 19,9 1,01 19,7 0,91 
N-Me 36,3 3,32 29,9 2,91 36,6 3,24 
O-Me 
      
threonine 1 172,7 
 
173,4 
 
172,7 
 
2 55,4 4,79 55,8 4,85 56,1 4,77 
3 68,4 4,15 68,6 4,07 68,4 4,13 
4 19,9 1,14 20,3 1,19 20,2 1,17 
proline/ 
homoproline 
1 173,6 
 
174,5 
 
173,8 
 
2 61,9 4,58 61,9 4,56 61,9 4,60 
3a 31,0 2,29 31,1 2,29 30,7 2,20 
3b 
 
2,15 
 
2,09 
 
2,26 
4 25,2 1,96 25,4 1,94 25,2 1,96 
5a 49,2 3,57 49,1 3,50 49,3 3,52 
5b 
 
3,51 
 
3,45 
 
3,63 
6a 
      
6b 
      
dehydrobutyrine 1 166,6 
 
166,6 
 
167,0 
 
2 131,9 
 
131,8 
 
131,8 
 
3 118,2 5,82 118,4 5,98 118,6 5,82 
4 12,9 1,72 13,1 1,71 13,0 1,73 
cysteine 1 170,3 
 
171,2 
 
170,9 
 
2 79,0 5,15 78,2 5,16 78,6 5,12 
3a 36,0 3,68 38,9 3,72 36,6 3,50 
3b 
 
3,48 
 
3,67 
 
3,74 
4-
methylazetidine-
carboxylic acid 
1 182,2 
 
178,9 
 
182,8 
 
2 61,1 4,90 61,0 4,75 61,2 4,93 
3a 31,3 2,33 31,2 2,28 31,2 2,33 
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3b 
 
2,04 
 
2,10 
 
2,06 
4a 25,6 2,24 24,9 2,07 25,7 2,23 
4b 
 
2,08 
   
2,07 
5a 48,3 3,98 48,3 4,06 48,2 3,96 
5b 
 
3,68 
 
3,91 
 
3,65 
leucine 1 173,2 
 
173,9 
 
173,2 
 
2 50,6 4,69 51,0 4,70 50,7 4,75 
3a 40,8 1,60 40,9 1,64 40,8 1,58 
3b 
 
1,50 
 
1,53 
 
1,51 
4 25,7 1,69 25,9 1,71 25,7 1,69 
5 23,5 0,97 23,5 0,99 23,5 0,97 
6 21,8 0,95 21,8 0,97 22,1 0,96 
alanine 1 173,9 
 
173,9 
 
171,7 
 
2 50,1 4,40 49,7 4,40 56,1 4,45 
3 18,8 1,38 19,3 1,33 63,1 3,82 
 
    
(Serine β-OH) 
glyceric acid 1 172,9 
 
172,4 
 
173,6 
 
2 70,8 4,41 71,6 4,39 71,1 4,50 
3a 66,1 4,41 66,9 4,56 66,7 4,47 
3b 
 
4,09 
 
4,18 
 
4,11 
 
 
Fig. S20 GC-MS analysis of the fatty acid component in previoprolide B. The 
total ion current (TIC) chromatogram is shown. 
 
Quantification of vioprolides  
    Aliquots of 100 µL were withdrawn from 25 mL bacterial cultures over a time 
course of 14 days. Each strain was cultivated in triplicates. Withdrawn sample 
portions were centrifuged for 10 min at 21000 g and 4 °C by using a Himac 
CT15E benchtop centrifuge (Hitachi Koki Co., Ltd., Japan), followed by 
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withdrawal of 80 µL of supernatant. These 80 µL samples were dried using an 
Eppendorf Concentrator plus (Hamburg, Germany) and the dried down samples 
were stored at -20 °C until measurement. Prior to measurement, all samples 
were reconstituted in 80 µL of MeOH in conical LC vials. All measurements 
were performed on a Dionex Ultimate 3000 RSLC system using a BEH C18, 
100 × 2.1 mm, 1.7 µm dp column (Waters, Germany). Separation of 5 µL 
sample was achieved by a linear gradient from (A) H2O + 0.1% fomic acid to 
(B) ACN + 0.1% formic acid at a flow rate of 600 µL/min and a column 
temperature of  45 °C. Gradient conditions were set as follows: 0-0.5 min, 
5% B; 0.5-9.5 min, 5-45% B; 9.5-10.5 min, 45-95% B; 10.5-11.5 min, 95%; 
11.5-11.8 min, 95-5% B; 11.8-13.5 min, 5% B. The eluent stream was diverted 
to waste during the first 7 min in order to minimize source contamination. UV 
spectra were recorded by a DAD in the range from 200 to 600 nm. The LC flow 
was split to 75 µL/min before entering the solariX XR (7T) FT-ICR mass 
spectrometer (Bruker Daltonics, Germany) using the Apollo II ESI source. In 
the source region, the temperature was set to 200 °C, the capillary voltage was 
0 V during the first 7 min and 4500 V after 7 min, the dry-gas flow was 4.0 
L/min and the nebulizer was set to 1.1 bar. After the generated ions passed the 
quadrupole with a low cutoff at 100 m/z they were trapped in the collision cell 
for 200 ms and finally transferred within 0.9 ms through the hexapole into the 
ICR cell. Captured ions were excited by applying a frequency sweep from 100 
to 1600 m/z and detected in broadband mode using a FID data size of 256k. 
Transient length was intentionally kept low to ensure a sufficient number (>14) 
of points per peak for quantification purposes.  
The calibration curves for external calibration were obtained using solutions 
of vioprolide B and D with concentrations in the range 100-0.01 ng/mL. Curve 
fitting was done using the Origin 2016 software package (OriginLab, 
Northampton, UK). Regression analysis was done using both linear and 
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quadratic regression models; a subsequent F-Test for model comparison was 
carried out to identify the most suitable model. A quadratic model was found to 
be appropriate for both analytes (α=0.05). Error bars are prediction intervals of 
the mean calculated concentrations obtained from three biological replicates at 
the indicated incubation times. Calculation of prediction intervals and limits of 
quantification was achieved using a custom Microsoft Excel 2010 sheet. The 
limit of quantification was iteratively calculated by employing the GRG 
nonlinear solving method with a convergence criterion of 2·10
-5
. The production 
titers of vioprolide B and D from Cb vi35 and heterologous hosts are shown in 
Fig. S21. 
 
Fig. S21 Quantification of vioprolide B and D from Cb vi35 and heterologous 
hosts. 
 
Strains and primers 
Table S4 Strains and primers used in this study 
Strains                                                          Characterization 
E. coli GB2005 E. coli strain for cloning, derivate strain of E. coli DHB101 
E. coli GB05-red E. coli GB2005 with redα, redβ, redγ and recA integrated into chromosome under 
control of arabinose inductive PBAD promoter [6] 
E. coli GBred-gyrA462 GB05-red, GyrA mutation of Arg462Cys [5] 
E. coli HS996::pUC-cosmid 
EK21 
E. coli HS996 carring the cosmid vector pUC-cosmid EK21; most part of vio gene 
cluster was located in cosmid EK21; AmpR 
E. coli GBred::pUC-zeoR-vioZ-
cosmid EK21 
E. coli GB05-red carring pUC-zeoR-vioZ-cosmid EK21; zeoR-vioZ cassette was 
inserted on pUC-cosmid EK21, the vioZ gene is integral; NeoR, ZeoR 
E. coli GBred::pUC-ampR-zeoR-
vioZ-cosmid EK21 
The neoR gene of pUC-zeoR-vioZ-cosmid EK21 was replaced by ampR; AmpR, ZeoR 
E. coli GBred::p15A-Tn5-kmR- E. coli GB05-red carring p15A-Tn5-kmR-vioD~orf9; vioD~orf9 were cloned on 
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vioD~orf9 p15A vector; KmR 
E. coli GBred::p15A-Tn5-kmR-
zeoR-vio 
E. coli GB05-red carring p15A-Tn5-kmR-zeoR-vio; the vio gene cluster was stitched 
and constructed on p15A vector; KmR, ZeoR 
E. coli GBred::p15A- Tps-BSD-
oriT- kmR-zeoR-vio 
E. coli GB05-red carring p15A-Tps-BSD-oriT- kmR-zeoR-vio; the Tps-BSD-oriT 
cassette was added on p15A-Tn5-kmR-zeoR-vio; KmR, ZeoR, BSDR 
E. coli GBred::p15A-Tps-BSD-
oriT-KmR-gentR-tetR-Ptet-vio 
E. coli GB05-red carring p15A-Tps-BSD-oriT-KmR-gentR-tetR-Ptet-vio on which 
gentR-tetR-Ptet was inserted before vioZ where zeoR was replaced; vioZ, vioA and 
vioD were mutated. KmR, GentaR, BSDR 
E. coli GBred-gyrA462::p15A-
Tps-BSD-oriT-Km-gentR-Ptet-
vio-ampccdB-vioD 
E. coli GBred-gyrA462 carring p15A-Tps-BSD-oriT-KmR-gentR-tetR-Ptet-vio-
ampccdB-vioD, the mutation site in vioD was substituted by ampR-ccdB; KmR, 
GentaR, AmpR, BSDR 
E. coli GBred::p15A-Tps-BSD-
oriT-Tn5-Km-gentR-Ptet-violig 
E. coli GB05-red carring p15A-Tps-BSD-oriT-KmR-gentR-tetR-Ptet-violig,  the vioD 
was repaired; KmR, GentaR, BSDR 
E. coli GBred-gyrA462::p15A-
Tps-BSD-oriT-Tn5-Km-gentR-
Ptet-violig 
E. coli GBred-gyrA462 carring p15A-Tps-BSD-oriT-KmR-gentR-tetR-Ptet-violig; 
KmR, GentaR, BSDR 
E. coli GBred-gyrA462::p15A-
Tps-BSD-oriT-Tn5-Km-gentR-
Ptet-vioAcmccdB-violig 
E. coli GBred-gyrA462 carring p15A-Tps-BSD-oriT-Tn5-Km-gentR-Ptet-
vioAcmccdB-violig,  the mutation site of vioA gene was replaced by cmR-ccdB 
cassette; KmR, GentaR, CmR, BSDR 
E. coli GBred::p15A-Ptet-
vioArecov-vio 
E. coli GB05-red carring the final vioprolides expression vector p15A-Tps-BSD-oriT-
Tn5-KmR-gentR-tetR-Ptet-vioArecov-vio, the mutation site in vioA was repaired; 
KmR, GentaR, BSDR 
E. coli GBred- gyrA462::p15A-
Tps-BSD-oriT-Tn5-Km-
vioZampccdB-vioArecov-vio 
E. coli GBred- gyrA462 carring p15A-Tps-BSD-oriT-Tn5-KmR-vioZampccdB-
vioArecov-vio, the gentR-tetR-Ptet cassette and the mutation site in vioZ were 
replaced by ampR-ccdB cassette; KmR, BSDR, AmpR 
E. coli GBred:: p15A-Ptn5-vio E. coli GB05-red carring the final vioprolides expression vector p15A-Tps-BSD-oriT-
Tn5-KmR-vio, the mutation sites in both vioZ and vioA were repaired; vio gene 
cluster was controlled by Ptn5 promoter; KmR, BSDR 
E. coli GBred- gyrA462::p15A-
Tps-BSD-oriT-Tn5-Km-gentR-
Ptet-vioZcmccdB-vioArecov-vio 
E. coli GBred-gyrA462 carring p15A-Tps-BSD-oriT-Tn5-KmR-gentR-tetR-Ptet-
vioZcmccdB-vioArecov-vio, the mutation site in vioZ was replaced by cmR-ccdB 
cassette; KmR, GentaR, BSDR, CmR, BSDR 
E. coli GBred:: p15A-Ptet-vio E. coli GB05-red carring vioprolide final expression vector p15A-Tps-BSD-oriT-Tn5-
KmR-gentR-tetR-Ptet-vio, the mutation sites in vioZ, vioA and vioD were repaired; 
vio gene cluster was controlled by Ptet promoter; KmR, GentaR, BSDR 
E. coli GBred::p15A-Ptet-
vioArecov-vio-orfNDelcmR  
E. coli GB05-red carring p15A-Ptet-vioArecov-vio-orfNDelcmR (N= 3, 4, 5, 6, 5&6, 
7, 8, 9 or 3~9); the orf3, orf4, orf5, orf6, orf5&6, orf7, orf8, orf9 or orf3~9 in the vio 
gene cluster was replaced with cmR gene; KmR, GentaR, CmR, BSDR 
E. coli GBred::p15A-Ptet-
vioArecov-vio-orfNDel  
E. coli GB05-red carring p15A-Ptet-vioArecov-vio-orfNDel (N= 3, 4, 5, 6, 5&6, 7, 8, 
9 or 3~9); the orf3, orf4, orf5, orf6, orf5&6, orf7, orf8, orf9 or orf3~9 in the vio gene 
cluster was deleted; KmR, GentaR, BSDR 
E. coli GBred-gyrA462::p15A-
Ptet-vioArecov-
vioA1mutcmccdB 
E. coli GBred-gyrA462 carring p15A-Ptet-vioArecov-vioA1mutcmccdB; the Glu 
(position 331) encoding codon GAG in the A1 domain was replaced by cmR-ccdB 
cassette; KmR, GentaR, CmR, BSDR 
E. coli GBred::p15A-Ptet-
vioArecov-vioA1E331D 
E. coli GB05-red carring p15A-Ptet-vioArecov-vioA1E331D; the position 331 in the 
A1 domain was mutated to Asp; Km
R, GentaR, BSDR 
E. coli GBred-gyrA462::p15A-
Ptet-vioArecov-NMTmutcmccdB 
E. coli GBred-gyrA462 carring p15A-Ptet-vioArecov-NMTmutcmccdB; the 
conservative Gly encoding codon GGA was replaced by cmR-ccdB cassette; KmR, 
GentaR, CmR, BSDR 
E. coli GBred::p15A-Ptet-
vioArecov-NMTmut 
E. coli GB05-red carring p15A-Ptet-vioArecov-NMTmut; the NMT domain in vio 
gene cluster was inactivated; KmR, GentaR, BSDR 
E. coli GBred-gyrA462::p15A-
Ptet-vioArecov-
vioA1mutcmccdB-NMTmut 
E. coli GBred-gyrA462 carring p15A-Ptet-vioArecov-vioA1mutcmccdB-NMTmut; 
the Glu (position 331) encoding codon GAG in the A1 domain was replaced by cmR-
ccdB cassette; the NMT domain in vio gene cluster was inactivated; KmR, GentaR, 
CmR, BSDR 
E. coli GBred::p15A-Ptet-
vioArecov-vioA1E331D-
NMTmut 
E. coli GB05-red carring p15A-Ptet-vioArecov-NMTmut; the position 331 in the A1 
domain was mutated to Asp and NMT domain was inactivated; KmR, GentaR, BSDR 
E. coli BL21 (DE3)::pCold-MtaA 
+ pGro7 
MtaA expressing strain; kindly provided by Dr. Hilda Sucipto; AmpR, CmR  
E. coli Rosetta (DE3)::pET28b-
STFP 
E. coli Rosetta (DE3) carring pET28b-STFP; FAAL-ACP-C-FkbH-PCP expression 
strain; faal-acp-c-fkbH-pcp with a sumo-tag and a TEV-protease cleavage site was 
constructed on expression vector pET28b; KmR 
E. coli Rosetta (DE3)::pET28b-
FP 
E. coli Rosetta (DE3) carring pET28b-FP; FAAL-ACP-C-FkbH-PCP expression 
strain; faal-acp-c-fkbH-pcp was constructed on expression vector pET28b; KmR 
E. coli Rosetta (DE3)::pET28b- E. coli Rosetta (DE3) carring pET28b-STFA; FAAL-ACP expression strain; faal-acp 
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STFA with a sumo-tag and a TEV-protease cleavage site was constructed on expression 
vector pET28b; KmR 
E. coli BL21 (DE3)::pET28b-
ACP 
E. coli BL21 (DE3) carring pET28b-ACP; ACP expression strain; ACP encoding 
sequence was constructed on expression vector pET28b; KmR 
E. coli BL21 (DE3)::pET28b-
STKP 
E. coli BL21 (DE3)  carring pET28b-STKP; FkbH-PCP expression strain; fkbH-pcp 
with a sumo-tag and a TEV-protease cleavage site was constructed on expression 
vector pET28b; KmR 
E. coli GBred::p15A-Ptet-vio-
FACdel 
E. coli GBred carring p15A-Ptet-vio-FACdel, the faal-acp-c tridomain of the vio gene 
cluster was deleted; KmR 
E. coli GBred-gyrA462:: p15A-
Ptet-vio-C4cmccdB 
E. coli GBred-gyrA462 carring p15A-Ptet-vio-C4cmccdB; the catalytic motif of C4 
domain was replaced by cmR-ccdB cassette; CmR, KmR 
E. coli GBred:: p15A-Ptet-vio-
C4H1mut 
E. coli GB05-red carring p15A-Ptet-vio-C4H1mut; the encoding codon CAT of the 
first His in the catalytic motif of C4 domain was mutated into Ala codon GCT; Km
R 
E. coli GBred:: p15A-Ptet-vio-
C4H2mut 
E. coli GB05-red carring p15A-Ptet-vio-C4H1mut; the encoding codon CAC of the 
second His in the catalytic motif of C4 domain was mutated into Ala codon GCC; 
KmR 
E. coli GBred:: p15A-Ptet-vio-
C4H3mut 
E. coli GB05-red carring p15A-Ptet-vio-C4H1mut; the encoding codon CAC of the 
third His in the catalytic motif of C4 domain was mutated into Ala codon GCC; Km
R 
M. xanthus DK1622 (ΔmchA) Heterologous host for vioprolide expression; Myxococcus xanthus DK1622; ΔmchA, 
the myxochromide A gene cluster was deleted; TetR 
M. xanthus::Ptet-violig M. xanthus with vio gene cluster Tn5-kmR-gentR-tetR-Ptet-violig integrated into 
chromosome; vioD repaired, vioA and vioZ mutated; TetR, KmR 
M. xanthus::Ptet-vio M. xanthus with vio gene cluster Tn5-kmR-gentR-tetR-Ptet-vio integrated into 
chromosome; vioZ, vioA and vioD were repaired; vio gene cluster was controlled by 
Ptet promoter; TetR, KmR 
M. xanthus::Ptn5-vio M. xanthus with vio gene cluster Tn5-kmR-vio integrated into chromosome; vioZ, vioA 
and vioD were repaired; vio gene cluster was controlled by Ptn5 promoter; TetR, KmR 
M. xanthus::Ptet-vio-int M. xanthus with vio gene cluster Tn5-kmR-gentR-tetR-Ptet-vio integrated at tetR site of 
the chromosome; vioZ, vioA and vioD were repaired; vio gene cluster was controlled 
by Ptet promoter; TetR, KmR 
M. xanthus::Ptn5-vio-int M. xanthus with vio gene cluster Tn5-kmR-vio integrated at tetR site of the 
chromosome; vioZ, vioA and vioD were repaired; vio gene cluster was controlled by 
Ptn5 promoter; TetR, KmR 
M. xanthus::vio-orfNDel M. xanthus with Tn5-kmR-gentR-tetR-Ptet-vioArecov-vio-orfNDel (N= 3, 4, 5, 6, 5&6, 
7, 8, 9 or 3~9) integrated into chromosome; the orf3, orf4, orf5, orf6, orf5&6, orf7, 
orf8, orf9 or orf3~9 in the vio gene cluster was deleted; vioZ mutated, vioA and vioD 
were repaired; TetR, KmR 
M. xanthus::Ptet-vioArecov-
A1E331D 
The vio gene cluster with mutated position 331 in A1 domain was integrated into 
chromosome; vioZ mutated, vioA and vioD were repaired; TetR, KmR 
M. xanthus::Ptet-vioArecov-
NMTmut 
The vio gene cluster with the inactivated NMT domain was integrated into 
chromosome; vioZ mutated, vioA and vioD were repaired; TetR, KmR 
M. xanthus::Ptet-vioArecov-
A1E331D-NMTmut 
The vio gene cluster with mutated position 331 in A1 domain and inactivated NMT 
domain was integrated into chromosome; vioZ mutated, vioA and vioD were repaired; 
TetR, KmR 
M. xanthus::Ptet-vio-FACdel The vio gene cluster with the faal-acp-c deletion was integrated into chromosome; 
vioZ, vioA and vioD were repaired;TetR, KmR 
M. xanthus::Ptet-vio-C4H1mut The vio gene cluster with the first His mutated in the catalytic motif of C4 domain was 
integrated into chromosome; vioZ, vioA and vioD were repaired;TetR, KmR 
M. xanthus::Ptet-vio-C4H2mut The vio gene cluster with the second His mutated in the catalytic motif of C4 domain 
was integrated into chromosome; vioZ, vioA and vioD were repaired;TetR, KmR 
M. xanthus::Ptet-vio-C4H3mut The vio gene cluster with the third mutated His in the catalytic motif of C4 domain 
was integrated into chromosome; vioZ, vioA and vioD were repaired;TetR, KmR 
Burkholderia DSM7029 Heterologous host for vioprolide expression; Burkholderia K481-B101 (ATCC 
53080; DSM 7029) 
Burkholderia DSM7029::Ptet-vio Burkholderia DSM7029 with vio gene cluster Tn5-kmR-gentR-tetR-Ptet-vio integrated 
into chromosome; vioZ, vioA and vioD were repaired;vio gene cluster was controlled 
by Ptet promoter; KmR 
Burkholderia DSM7029::Ptn5-
vio 
Burkholderia DSM7029 with vio gene cluster Tn5-kmR-vio integrated into 
chromosome; vioZ, vioA and vioD were repaired; vio gene cluster was controlled by 
Ptn5 promoter; KmR 
Burkholderia DSM7029::vio-
orfNDel 
Burkholderia DSM7029 with Tn5-kmR-gentR-tetR-Ptet-vioArecov-vio-orfNDel (N= 3, 
4, 5, 6, 5&6, 7, 8, 9 or 3~9) integrated into chromosome; the orf3, orf4, orf5, orf6, 
orf5&6, orf7, orf8, orf9 or orf3~9 in the vio gene cluster was deleted; vioZ mutated, 
vioA and vioD were repaired;  KmR 
Pseudomonas putida KT2440 Heterologous host for vioprolide expression; AmpR 
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P. putida KT2440::Ptet-vio P. putida KT2440 with vio gene cluster Tn5-kmR-gentR-tetR-Ptet-vio integrated into 
chromosome; vioZ, vioA and vioD were repaired;vio gene cluster was controlled by 
Ptet promoter; AmpR, KmR 
P. putida KT2440::Ptn5-vio P. putida KT2440 with vio gene cluster Tn5-kmR-vio integrated into chromosome; 
vioZ, vioA and vioD were repaired; vio gene cluster was controlled by Ptn5 promoter; 
AmpR, KmR 
Primers  
ET21-cyclo-up CCTCGTGTGTCCGGACTAC 
Vio-5 GCCGCCTTCGAGCTCTAC 
vio-cyclo-up CTCGAGTTGTTCCTCGAGTACG 
vio-cyclo-down CGTAGAGACAGCCGAAAGAAGG 
Vio9-Cfor  CGCCTGTGGTTCCTGCATCA 
Vio9-Crev AGGGTCATGTACAGCGTGGC 
Vio-9 AGTGGCTCGAGAGTGCTTGTGACGAG 
Vio-10 AGGAGCTCATCGAGCAGATCGGCATC 
Vio-13 AGATGGCTCGACAGCTGCGTG 
Vio-14 GATGATCGCGACGGACGTTTCC 
V-zeo AGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTAG
CTAGCCTTAAGAGCACGTGTTGAC 
V-overlap-3 GGAGTCCTACTCAGAGTCTCAGTCCTGCTCCTCGGC 
V-overlap-5 GCCGAGGAGCAGGACTGAGACTCTGAGTAGGACTCC 
V-amp-5 GAGCGCCGCCGCCTTCTCGAGGAGAAGCGCAAGAACAGGAGGCAGCCGT
GACATATGCTAGCTGACCTGT 
V-amp-3 TGGCAGGTTGGGCGTCGCTTGGTCGGTCATTTCGAACCCCAGAGTCCCGCC
TACCAATGCTTAATCAGTG 
VioD-15A CCTCGTCCGCCGCGTCCTTCAGCACCTCCTCGAATGCCGCCTGGGCCTCCG
GGAACCGGCACAGCTCGAACAGGGCAATGGCGCTAGCGGAGTGTATACTG 
vioD-neo GACTCCTCGAGGAGGTACTGGAGCAGCTCGAGATCGTCCCCGGTGAGCGA
TGCCGCAGAATCCCTCTCGTGCTTCATATCTCGCCTCCTTAAGCCTAGGTC
AGAAGAACTCGTCAAGAAG 
Vio-Tps5 TCGAATGCCGCCTGGGCCTCCGGGAACCGGCACAGCTCGAACAGGGCAAT
GGCGAACCTCATTCCCTCATGATAC 
P15AUpSeq AGCACTTCACTGACACCCTCATC 
genTetVi5 TTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGAAGG
CACGAACCCAGTTGAC 
genTetVi3 TCAACCGCTCGATGAGCTGGTGCATTGAGCCGGTCGACACCGACATGAGT
GCCTCTTCTCTATCACTGATAGG 
vioCDlig15 ACGTTCCATGTGGAGCTGCCAC 
vioCDlig13 CGCAGAATCCCTCTCGTGCTTCACGGCTGCCTCCTGTTCTT 
vioCDlig25 AAGAACAGGAGGCAGCCGTGAAGCACGAGAGGGATTCTGCG 
vioCDlig23 TCATGTGATAGGCGGCGCTCTC 
amp-ccdB5 CGCCGCCGCCTTCTCGAGGAGAAGCGCAAGAACAGGAGGCAGCCGTGATT
TGTTTATTTTTCTAAATAC 
amp-ccdB3 AGCGATGCCGCAGAATCCCTCTCGTGCTTCATATCTCGCCTCCTTAAGCCA
GCCCCATACGATATAAGTTG 
XmaJIhomolog-cm5 AGTGAGCAGGAGGCTCCTCGCACGGCGCTCGAAGCGGAGCTGGCCCGTAT
CCTAGGGAGGAGCGCAGTCACCTCTAGATG 
Homolog-cmccdb3 CGCCCAGGTCGAAGAACCGGTCATCACGGCCGACACGCTCCAGGCCGAGC
AAGCCCGCTCATTAGGCGGGCTG 
vioAseq5 TATGTGGTGCCACACGCCGGAGGAC 
vioAseq32 CGTCACCGGCCTGACGTGGCACCAGG 
orf3Del-cm5 GAACCACGGTTACGAAATCATCACGGTCGAGGTCCCGACCACGGAGCACC
TAGGGAGGAGCGCAGTCACCTCTAGATG 
orf3Del-cm3 TCACTCCGGCTGGTAGACCTGCGTGCGAGCCATCAGCTCGCGAGAGAAAC
GCCTAGGTGGTTATGTGTGGGAGGGCTAACC 
orf4Del-cm5 ATGGATGAATTCAACCGAATCTGGTCCGGGCTCGGCGCTTCCGTGCGCAA
GCCTAGGGAGGAGCGCAGTCACCTCTAGATG 
orf4Del-cm3 TCAGGAGCTCTGCGCCGGCTCGCTCCAGGGGAGGTGGCCCTCGGGAGTTC
CCCTAGGTGGTTATGTGTGGGAGGGCTAACC 
orf5Del-cm5 AGTCCCACCTGCGCCGCTGTTCCACGCGGCGCGCATTGGCAGGCCATGACC
TAGGGAGGAGCGCAGTCACCTCTAGATG 
orf5Del-cm3 CCCTGACCCTGCGCATAGAAGTCGAGCGTGCTCATGCCTTGCTCCCGGCCC
TAGGTGGTTATGTGTGGGAGGGCTAACC 
orf6Del-cm5 GCACGCTCGACTTCTATGCGCAGGGTCAGGGCGACCGGCTCATCGACCCCT
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AGGGAGGAGCGCAGTCACCTCTAGATG 
orf6Del-cm3 GATTCCCAGCGGCTTCCGGCCGCTGGCCCTTCACTGCACCGATCGACGCTC
CTAGGTGGTTATGTGTGGGAGGGCTAACC 
orf7Del-cm5 GCGGCCGGAAGCCGCTGGGAATCAACAGCAAGGAGAACGTGCTTATGGCG
CCTAGGGAGGAGCGCAGTCACCTCTAGATG 
orf7Del-cm3 CGTAAGCAAACAGCGGGTGTGTGGAATCAGAGCTTGTTCAGGATCTTCCG
CCTAGGTGGTTATGTGTGGGAGGGCTAACC 
orf8Del-cm5 CCACACACCCGCTGTTTGCTTACGGAGAACTGAACATGGAAACACCCAAC
CCTAGGGAGGAGCGCAGTCACCTCTAGATG 
orf8Del-cm3 TCCTCCCTGAACCGGGAGGCCGTCCTCGTCGTGGCTCAGTACCGCCAGCCC
CTAGGTGGTTATGTGTGGGAGGGCTAACC 
orf9Delcm5 GGCCTCATCCAGTCCCTCAGGGGTGCACGAGGAGCATCAGGAGCAGTCAC
CTAGGGAGGAGCGCAGTCACCTCTAGATG 
orf9Delcm3 CATTGCCCTGTTCGAGCTGTGCCGGTTCCCGGAGGCCCAGGCGGCATTCGC
CTAGGTGGTTATGTGTGGGAGGGCTAACC 
orf3Delcheck5 GGACATGAATGCGGGAGTTATG 
orf4Delcheck5 TCGCGAGCTGATGGCTCGCAC 
orf34Delcheck3 GAGGTTCTGCTGCTCGATGAAC 
orf56Delcheck51 TCGTCAACACGCTGGGAACTCC 
orf56Delcheck52 CAGCTCTTCGAACAGCTCCAGC 
orf56Delcheck3 GCGCCATAAGCACGTTCTCCTTG 
orf78Delcheck5 ATGTTCGAGCCCTGGCGCCCTTG 
orf78Delcheck3 GCTCCTGATGCTCCTCGTGCAC 
orf9Delcheck3 CATTGCCCTGTTCGAGCTGTGCC 
Ptetviozcmccdb5 TTGATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGAAGAGGCACTCC
TAGGGAGGAGCGCAGTCACCTCTAGATG 
Ptetviozcmccdb3 GCGGGTCGTAATGGAGCAGGCTCTGCATCAACCGCTCGATGAGCTGGTGC
CTAGGAAGCCCGCTCATTAGGCGGGCT 
Ptetviozrecov5 TTGATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGAAGAGGCACTCA
TGGAGACGCTGCTCATTTCGG 
vioZrecov3 CCTTTTGCGGACCTCGATGGACC 
vioZampccdB5 CCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGATT
TGTTTATTTTTCTAAATAC 
vioZampcounter3 GCGGGTCGTAATGGAGCAGGCTCTGCATCAACCGCTCGATGAGCTGGTGC
AGCCCCATACGATATAAGTTG 
vioZrecov5 CCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGACT
TAAGGAGGTACAGATTATGGAGACGCTGCTCATTTCGG 
VioA1mutcmccdB5 CTCGACGTGCCGCTGTACAACCTATACGGCCCGACAGAGGCGGCGATCGA
CCTAGGGAGGAGCGCAGTCACCTCTAGATG 
VioA1mutcmccdB3 CGGGAGGCAGGGGCGCGAGTTCCCGATCGAGCACGTGGAGTTGCGTGTTG
CCTAGGAAGCCCGCTCATTAGGCGGGCT 
VioA1E-D5 CTCGACGTGCCGCTGTACAACCTATACGGCCCGACAGAGGCGGCGATCGA
CGTCAGCGCCTGGCAGTGC 
VioA1E-D3 TCTCCAGCGATACCGGGAGGCAG 
NMTmutcmccdB5 TGGCTCACATCCTCTCGCTCGCGCCGGAGCGGGTGTTGGAGATCGGGTGTC
CTAGGGAGGAGCGCAGTCACCTCTAGATG 
NMTmutcmccdB3 AGGATGATCGCGTCGTAGCTGCCCGGTTCGAACCCGCTGACGTCATCCGCC
TAGGAAGCCCGCTCATTAGGCGGGCT 
NMT-G-R-5 TGGCTCACATCCTCTCGCTCGCGCCGGAGCGGGTGTTGGAGATCGGGTGTC
GAACGGGCCTCCTGCTGC 
NMT-G-R-3 CACCGAGTTCAGGATGATCGCGTC 
Module1-NheI-5  GCTAGCTAGCATGACTGCTTCCGTGAGTATCAGCC 
Module1-NotI-3 ATAAGAATGCGGCCGCGATTGCCCCCTGCTCGGCGTGGATG 
FA-AatII-5  GGAGGACGTCACCGCGCAGCATG 
FA-NotI3 AGTGCGGCCGCCTACCCACCAGGCCCGGCGGAGGGCTTC 
HisACP-NcoI5 ATACCATGGGCCATCATCATCATCATCACGACGCGGGCGGCTCCAGGGCG 
FA-NotI3 AGTGCGGCCGCCTACCCACCAGGCCCGGCGGAGGGCTTC 
KP-NheI5 CCTAGCTAGCATGTTCCAGGAGCGTGAGGGCCTGAC 
KP-NotI3 AGTGCGGCCGCCTAGATTGCCCCCTGCTCGGCGTGGATG 
VC4-cm5 
TCGAGGAGGATCGCAAGCGTGGCTTCGACTTCTCGTCTGCGCCCCTGATGC
CTAGGAAATAAATCCTGGTGTCCCTGTTGA 
VC4-ccdB3 
CTCCTCGAAGACAGGCTCACCGTCGATACGCTCGGAGAGCGCACGATCCA
CCTAGGCAAAAAAAAGCCCGCTCATTAGGCG 
VC4I-5 TCGAGCGCTTCCTCGAGGAGGATC 
VC4II-5 CCTGCTCCTGGACGGCTGGAG 
VC4II-3 TGAGCCGCTGCTCCTCGAAGAC 
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VC4H1I-3 CTCCAGCCGTCCAGGAGCAGGTGGTGAGCACTCCAGAC 
VC4H2I-3 CTCCAGCCGTCCAGGAGCAGGTGGGCATGACTCCAGAC 
VC4H3I-3 CTCCAGCCGTCCAGGAGCAGGGCGTGATGACTCCAGAC 
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3. DISCUSSION 
3.1 General scope of this work 
Natural products from myxobacteria are an abundant resource in the 
development of anti-infective and anticancer pharmaceuticals. The present thesis 
dealt with identification, elucidation and engineering of the biosynthetic 
pathway of vioprolides from C. violaceus Cb vi35. Heterologous expression was 
applied to validate the biosynthetic pathway and improve the production yield. 
Site-directed mutagenesis was carried out to expand the structural diversity. 
Biochemical investigations were performed to characterize the unusual initiation 
module responsible for the formation of previoprolides.  
 
3.2 Insights into vioprolide biosynthesis 
     A big part of microbial natural products originate from PKS and (or) NRPS 
gene clusters. The genetic information of microorganisms became easily 
accessible in the recent years due to the development of next generation DNA 
sequencing technologies [1, 2]. Natural product biosynthetic gene clusters are to 
some extent predictable from microbial genomes with the aid of several 
bioinformatics tools such as antiSMASH [3], CLUSEAN [4], ClustScan [5], 
SBSPKS [6] and NRPSpredictor [7]. In this study, the genome sequence of C. 
violaceus Cb vi35 was obtained by Illumina MiSeq sequencing. In silico 
analysis of the Cb vi35 genome by antiSMASH identified a putative NRPS 
pathway producing a compound with a similar skeleton to vioprolide. The 
pathway is composed of two unusual modules and eight NRPS modules. Ten 
elongation steps on the NRPS machinery lead to the assembly of previoprolides, 
the precursors of vioprolides. 
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3.2.1 Assembly initiation 
The assembly of vioprolides starts with the activation of long chain fatty acids. 
The lipid side chain is recruited from the fatty acid pool by the starting fatty 
acyl-AMP ligase (FAAL) domain of which the function was verified by in vitro 
biochemical investigations. FAALs are a new fatty acid activating enzyme 
family. They are firstly reported in Mycobacterium tuberculosis (Mtb) to 
activate and transfer long chain fatty acids to the carrier proteins of 
multifunctional PKSs [8]. Similar domains are also identified in other 
biosynthetic pathways such as mycosubtilin [9], alkylresorcylic acid [10] and 
telomycin [11]. FAALs are cognate proteins of fatty acyl-CoA ligase (FACL) 
with tiny difference in structure but play distinct roles. FACLs mainly involve in 
primary metabolism in Mtb, whereas FAALs take part in the biosynthesis of 
secondary metabolites such as phthiocerol dimycocerosates (PDIMs), sulfolipids, 
mycolic acids and mycobactin [12, 13]. The crystal structures of FACL and 
FAAL from Mtb reveal a large N-terminal domain and a small C-terminal 
domain [12–14]. The N-terminal domain contributes to AMP binding and fatty 
acid activation, whereas the C-terminal domain includes a CoA binding pocket 
and catalyzes fatty acyl-CoA ligation. In FACL, the C-terminal domain moves 
towards the N-terminal to ligate the activated acyl chain with CoA. A strong 
hydrophobic insertion motif, however, blocks the crosstalk between the two 
subdomains in FAAL and leads to the failure of acyl-CoA formation [13]. 
Indeed, sequence analysis revealed an insertion motif between the two 
subdomains of vioprolide FAAL (Fig. 3.1). The strong hydrophobic insertion 
loop between the two subdomains is more intuitive to be visualized from 3D-
structural alignments (Fig. 3.2). The vioprolide FAAL is thus supposed to load 
fatty acyl moiety to the ACP domain without forming fatty acyl-CoA 
intermediates, which is also supported by the results from in vitro biochemical 
investigations. 
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Fig. 3.1 Sequence alignment of myxobacterial FAALs with other reported 
FACLs and FAALs. The borders of N-terminal and C-terminal domains are 
indicated with arrows; insertion motifs are labeled with a green bar, and the 
insertion motif in vioprolide FAAL is highlighted in a pink box. Only part of 
213 myxobacterial FAALs is shown here. 
 
Fig. 3.2 Structure alignment of vioprolide FAAL (vioFAAL) with other reported 
FAALs. 1-3, alignment of vioFAAL with LpFAAL (Legionella pneumophila 
FAAL, PDB: 3KXW), EcFAAL (E. coli FAAL, PDB: 3PBK) and MtFAAL (M. 
tuberculosis FAAL, PDB: 3T5A), respectively; 4, enlarged insertion loop in 
vioFAAL. Strong hydrophobic insertion motifs are indicated with white boxes; 
N, N-terminal domain; C, C-terminal domain. 
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3.2.2 Glycerate incorporation and esterification 
Glycerate is diverted to vioprolide assembly line by the FkbH domain in the 
module 2. FkbH-like proteins belong to haloacid dehalogenase (HAD) 
superfamily, which sequentially incorporate D-1, 3-biphosphoglycerate from the 
glycerol pool to form D-3-phosphoglyceryl-S-FkbH intermediates, then act as 
phosphatases to generate D-3-glyceryl-S-FkbHs, and finally transfer the D-
glyceryl moiety to carrier proteins [15, 16]. FkbH-like proteins are also found to 
incorporate glyceryl units in the biosynthesis of several other natural products 
[15-24]. In vioprolide biosynthesis, the activated D-glycerate is the acceptor 
substrate of the C1 domain which is, however, an 
L
CL C domain. Conversely, the 
D-glycerate is isomerized to L-glycerate which is the donor substrate of the 
D
CL 
C2 domain. Similar situation was also discovered in cystomanamide biosynthetic 
machinery [23]. The 
D
CL C5 domain of cystomanamide assembly line uses D-
glycerate as the acceptor substrate which is the donor substrate of the 
L
CL C6 
domain. As glycerate is different from amino acids which are the common 
substrates of C domains, the configuration of glycerate probably has no effect on 
the condensation. Besides, the prediction of the C1 and C2 domain might be 
inaccurate due to the insufficient C domains with the same substrate specificity. 
The fatty acyl-glycerate in previoprolide structure is similar to the acyl-
glycerol in phospholipids. Glycerol acylation in the biosynthesis of 
phospholipids is catalyzed by glycerol-3-phosphate acyltransferase (GPAT) [25], 
whereas in vioprolide biosynthesis this process is catalyzed by a C domain. To 
the best of our knowledge, this is unique in secondary metabolism. To 
investigate the glycerate esterification function of the C1 domain, we purified the 
related protein FAAL-ACP-C-FkbH-PCP from E. coli. The whole protein, 
however, was unstable and could not be detected by LC-MS so that the mass 
shift of the intermediates-attaching protein was indistinguishable from the intact 
protein. Cysteamine therefore was applied to release the intermediates mildly 
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from the carrier proteins. The successful detection of the released fatty acyl-
glycerate by UPLC-HRMS confirmed the glycerate esterification function of the 
C1 domain. Biosynthesis of natural products by PKS and NRPS machineries 
could involve dozens of reactions without generating free intermediates [26]. 
The mild release of carrier protein-bound intermediates with cysteamine 
provides a feasible way to investigate the individual reaction in biosynthetic 
pathways. 
C domains play a critical role in the peptide chain extension in NRPs 
biosynthesis by forming a covalent bond between two carrier protein-bound 
substrates. Although C domains mostly catalyze amide bond formation between 
two amino acids, ester bond forming C domains (EBFCs) were also identified 
and characterized in the biosynthesis of fumonisin [27], C-1027 [28, 29] and 
cryptophycin [30]. According to the assembly lines and the final products, 
EBFCs are also supposedly involved in the biosynthesis of some other natural 
products such as enniatin [31, 32], FK520 [33] and antimycin [34]. Substrate 
recognition between these EBFCs could vary widely. For example, fumonisin 
EBFC (in FUM14) catalyzes the condensation between tricarboxylic acid and 
fumonisin backbone; C-1027 EBFC (SgcC5) condenses (S) -3-chloro-5-
hydroxy-β-tyrosine with (R) -1-phenyl-1,2-ethanediol; and FK520 EBFC is 
supposed to catalyze intramolecular lactonization. Phylogenetic analysis showed 
no tight evolutionary relationship between these EBFCs, although several 
EBFCs catalyzing similar substrates could be classified into the same clade (Fig. 
S10). The catalytic motif of the EBFCs could be different from the consensus 
HHXXXDX14Y (Fig. S11). The second His-residue of the catalytic motif is 
usually critical for amide bond formation, and the Asp-residue is important for 
structural stabilization [35–37]. The Asp-residue is highly conserved in the 
EBFCs, whereas the second His-residue is changed to Leu in beauvericin EBFC 
and to Tyr in oxazolomycin EBFC (Fig. S11). It is unknown which residue takes 
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over the deprotonation function of the second histidine and catalyzes the 
formation of the ester bond. The blurry relationship between the protein 
sequence of EBFC and the distinctive function suggests that NRPS machinery is 
more diverse and complicated than expected. Mechanistic characterization of 
EBFCs should contribute to the generation of novel compounds by 
combinatorial biosynthesis in the future. 
 
3.2.3 Proposed function of lipid side chain 
    The lipid chains of previoprolides were hydrolyzed after assembly. Precursor 
maturation was also discovered in the biosynthesis of xenocoumacin [38], 
pyoverdine [39, 40], colibactin [41] and naphthyridinomycin [42], the N-
terminal fatty acid or aminoacyl chains of their precursors are excised after 
assembly by periplasmic proteases XcnG, PvdQ, ClbP and NapG, respectively. 
Caerulomycin A [43], quinocarcin [44] and telomycin [11] are also synthesized 
as precursor before being trimmed by the amidohydrolase CrmL, peptidase 
Qcn1 and acylase Tem25, respectively. In addition, biosynthesis of didemnin 
[45], saframycin [46] and nocardicin [47] involve similar precursor maturation 
process but the respective protease is unknown. Several proteases similar to 
XcnG, PvdQ, ClbP, CrmL, NapG or Tem25 were found in C. violaceus Cb vi35 
and M. xanthus DK1622 genomes. The lipid chains of previoprolides may be 
hydrolyzed by one of these enzymes before extracellular secretion. 
The activation of fatty acids is probably essential to vioprolide biosynthesis. 
Deletion of the FAAL-ACP-C tridomain abolished the production of vioprolides 
(Fig. 3.3), although the abolishment of vioprolide production may also result 
from incorrect protein folding of the shortened assembly line. The activation of 
fatty acids may provide a high potential energy to trigger the initiation of 
assembly line and drive the biosynthesis towards the C-terminus. In addition, the 
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fatty acids may control the regioselectivity of the TE domain in the biosynthesis 
of previoprolides. The TE-mediated macrocyclization takes place only between 
the -COOH group of the methyl-valine and the β-OH group, rather than the α-
OH group, of the glycerate. Meanwhile, no cyclization was discovered between 
the -COOH group of the methyl-valine and the β-OH group of the serine during 
mutagenesis of hydroxyl-vioprolides. Similar instance was also found in the 
biosynthesis of calcium dependent antibiotics (CDA) in which the lipid chain 
length (C6) is critical to determine the regioselectivity of TE domain [48, 49]. 
The acylation thus prevented the incorrect cyclization and ensured the final 
structure. In several natural products biosynthesis such as xenocoumacin and 
amicoumacin [50], acylation serves as a self-protection group so that the 
prodrug is nontoxic to the producer. However, the lipid side chain in 
previoprolide is more likely to serve as a guide for exportation, because no 
obvious change in cytotoxicity was observed in the acylated vioprolide B. The 
structure of the acylated glycerate in previoprolides simulates phospholipids ‒ 
one of the major components of cell membrane. Membrane-guiding and 
extracellular secretion prevented the accumulation of vioprolides in cytosol and 
avoided the potential feedback inhibition on the expression of the vio gene 
cluster. 
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Fig. 3.3 HPLC-MS analysis of vioprolides from ∆FAAL-ACP-C mutants. The 
information of the muntant M. xanthus::Ptet-vio-FACdel (∆FAAL-ACP-C) is 
shown in the strain list in supplementary. M. xanthus DK1622 (∆mchA) was set 
as negative control, M. xanthus::Ptet-vioArecov-vio was set as positive control. 
EIC m/z for 849.4 [M+H]
+
 (vioprolide D and isomer) and 863.4 [M+H]
+
 
(vioprolide B and isomer) are shown. Intensity is adjusted to the same range. 
 
3.3 Heterologous expression of the vioprolide biosynthetic pathway  
We initially attempted to validate the vio gene cluster in the native producer 
by gene knock-out. Genetic manipulation, however, was inaccessible in C. 
violaceus Cb vi35. Therefore, we tried to clone the putative vio gene cluster and 
express it in heterologous hosts. The cloning was not straightforward because of 
the large size of the vio gene cluster. Only a part of the gene cluster was 
obtained by screening the cosmid library, and the remaining parts were cloned 
by PCR and Red/ET recombination. Red/ET recombination is a homologous 
recombination-based genetic engineering method, which has an advantage to 
edit DNA sequence of interest precisely without limit of the targeting sites [51–
53]. It has recently been developed as a simple and fast method to clone natural 
product biosynthetic gene clusters directly from genomic DNA [54–56]. Most of 
the modifications on the vio gene cluster were finished by Red/ET 
recombination. 
3. Discusstion 
 
121 
 
Heterologous expression reveals great advantages in characterization of 
biosynthetic pathways. The vio gene cluster was validated by successful 
expression in heterologous hosts. The core gene cluster (vioZ, vioA~D) was also 
determined by means of gene knock-out combined with heterologous expression. 
Furthermore, the production titer of vioprolides increased significantly in 
heterologous hosts M. xanthus DK1622 (ΔmchA) and Burkholderia DSM7029. 
Especially in M. xanthus::Ptet-vio, the overall production of vioprolides 
increased around 8-fold comparing with the native producer. The heterologous 
hosts grow faster than the native producer and the regulation network on the vio 
gene cluster was eliminated by replacing the native promoter with constitutive 
Ptet or Ptn5 promoter. The constitutive promoter ensured constant transcription 
of the vio gene cluster. In addition, the heterologous host M. xanthus DK1622 is 
evolutionarily close to C. violaceus Cb vi35. Both strains belong to 
Cystobacteraceae in the order Myxococcales. The GC content of the vio gene 
cluster (68.9%) is the same with the genome of M. xanthus DK1622. The vio 
gene cluster probably adapted well in M. xanthus DK1622 thus achieving a high 
expression level. Weak genetic adaptation or inefficient transcription of the vio 
gene cluster in P. putida and E. coli is probably the reason of the low and null 
production yield, promoter exchange or codon optimization may improve the 
vioprolide production. 
 
3.4 Production improvement via bioprocess optimization  
    The successful expression of the vio gene cluster in M. xanthus is a good 
starting point to increase the production yield further by bioprocess optimization. 
Although the vio gene cluster was successfully expressed in M. xanthus DK1622 
(ΔmchA) after chromosomal transposition, it is unclear whether the transposition 
disrupted endogenous genes and affected vioprolide production. The vio gene 
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cluster was therefore integrated at the tetR site in the chromosome of M. xanthus 
DK1622 (ΔmchA) by homologous recombination to avoid interrupting other 
native genes. Similar to transposition mutants, the tetR integration mutants M. 
xanthus::Ptet-vio-int and M. xanthus::Ptn5-vio-int also successfully produced 
vioprolides (Fig. 3.4). The tetR integration mutants were sent to our collaborator 
in HZI (Braunschweig) for bioprocess optimization. Their preliminary results 
from bioreactor revealed that the overall production of vioprolides increased to 
almost 1 g/L via bioprocess optimization on the mutant M. xanthus::Ptn5-vio-int 
(unpublished). Further optimization on fermentation conditions could probably 
achieve a higher production titer. Moreover, considering the Ptet promoter is 
more efficient than Ptn5 promoter to drive the vio gene cluster in M. xanthus, 
the mutant M. xanthus::Ptet-vio-int has a potential to produce vioprolides in a 
higher yield. 
 
Fig. 3.4 HPLC-MS analysis of vioprolides produced by M. xanthus::Ptet-vio-int 
and M. xanthus::Ptn5-vio-int. The production of vioprolide B-D is indicated 
with dashed lines, extracted ion chromatogram (EIC) m/z for 849.4 [M+H]
+
 
(vioprolide D and isomer) and 863.4 [M+H]
+
 (vioprolide B and isomer) is 
shown. M. xanthus DK1622 (ΔmchA) was set as negative control. Intensity is set 
to the same range. 
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3.5 Creation of molecular diversity by mutagenesis 
So far four types of vioprolides have been reported from C. violaceus Cb vi35. 
In this work, we also identified linear Me-vioprolide B, linear vioprolides, 
previoprolides and linear previoprolides in the native and heterologous 
producers (Fig. 3.5). The linear previoprolides may be a result of direct release 
from the TE domain and (or) ring opening of the circular previoprolides, 
whereas linear vioprolides are probably hydrolyzed from linear previoprolides 
and (or) circular vioprolides.  
NRPS machineries may show some substrate tolerance [57]. A-domains are 
critical for substrate selection and activation. Novel derivatives could thus be 
obtained by altering the specificity-conferring code of A domains, as 
represented in the engineering of luminmide [58], gramicidin S [59], 
hormaomycin [60], calcium dependent antibiotics (CDA) [61], just to name a 
few examples [62]. In this work, vioprolides B1~D1 were generated by site-
directed mutagenesis in the A1 domain; vioprolides B2~D2 were produced by 
inactivation of the NMT domain; and vioprolides B3~D3 were created by 
mutating both A1 and NMT domains. Similar to the linear vioprolides produced 
by the native vio gene cluster, linear derivatives were also found in the site-
mutated mutants (Fig. 3.5). The additional –OH group in the position 2 of 
vioprolides was achieved by altering the position 331 of the analine activating 
A1 domain. Resulting incorporation of serine instead of analine in the molecule 
increased the hydrophilicity of vioprolide B1 and resulted in around 100-fold 
less cytotoxicity than vioprolide B. Although the mode of action of vioprolide B 
is unclear at present, the addition of the –OH group probably interferes with the 
target binding site thus reduces the cytotoxicity. The compounds identified and 
generated in this study are summarized in Fig. 3.5. The production of vioprolide 
derivatives displays the potential to create more novel structures by engineering 
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the NRPS machinery. The expanded chemical diversity provided a compound 
library for candidate drug screening in the future. 
 
Fig. 3.5 Heterologous expression of vio gene cluster and the compounds 
generated in this study. Vioprolide B (6.6 mg), vioprolide D (15.7 mg), linear 
Me-vioprolide B (3 mg), vioprolide B1 (1.4 mg), vioprolide D1 (2.6 mg) and 
previoprolides (1.2 ~ 11.9 mg) were isolated from 10 L cultures of M. xanthus 
mutants, whereas others were limited to LC-MS and MS/MS characterization 
due to the low abundancy. Vioprolide D, linear Me-vioprolide B, vioprolide D1 
and previoprolide B were validated by NMR. 
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3.6 Potential of lipopeptide biosynthesis in myxobacteria 
FAAL-like proteins could serve as probe to screen candidate lipopeptide 
biosynthetic gene clusters in microbes, because their main function is activation 
of fatty acids in secondary metabolites biosynthesis. Alignment of vioprolide 
FAAL protein sequence in our in-house database displayed 244 myxobacterial 
proteins annotated as FACL. Detailed sequence analysis revealed that 213 of 
them are factually FAAL with distinctive insertion motifs (Fig. 3.1). Sixty eight 
of the 213 FAALs locate in NRPS or PKS/NRPS hybrid gene clusters (Fig. 3.6), 
whereas the others are discrete. Statistical analysis showed that Corallococcus 
and Sorangium species contain many FAAL-containing gene clusters (Fig. 3.6). 
The identified FAAL-containing gene clusters are listed in Table 3.1. Although 
FAAL-activated fatty acids may not exist in the final products, they could be 
involved in the biosynthesis of lipopeptide precursors. These findings suggested 
considerable undiscovered lipopeptide diversity in myxobacteria. Up to now, 
most of the identified lipopeptides are from Bacillus, Pseudomonads and 
Streptomyces etc. Only three classes of lipopeptides have been identified from 
myxobacteria (myxochromides, cystomanamides and previoprolides; 
cystomanamides and previoprolides are not lipopeptide in the strict definition). 
The potential of lipopeptide biosynthesis in myxobacteria is probably severely 
underestimated. 
 
Fig. 3.6 Statistical analysis of the 68 FAAL-containing gene clusters in 
myxobacteria. The FAAL-containing gene clusters were retrieved from our in-
house Mxbase. The number of the gene clusters and the respective species are 
shown in the left side; the type of of the 68 FAAL-containing gene cluster is 
shown in the right side. 
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Table 3.1 FAAL-containing gene clusters identified in our in-house database 
Strain FAAL-containing gene cluster* 
Angiococcus disciformis AngGT8 BSYN309, BSYN315 
Aetherobacter unclassified MSr9329 BSYN609 
Aetherobacter unclassified MSr9335 BSYN666 
Aetherobacter fasciculatus MSr9337 BSYN626 
Corallococcus unclassified MCy10984 BSYN459, BSYN467, BSYN468, 
BSYN474, BSYN478, Corramycin 
Corallococcus coralloides Ccc1071 BSYN5, BSYN3, BSYN13 
Corallococcus coralloides MCy9080 BSYN98, BSYN101, BSYN99, BSYN98 
Corallococcus coralloides ST201330 BSYN768, BSYN764 
Cystobacter unclassified MCy9101 BSYN587 
Cystobacter velatus Cbv34 BSYN381 
Cystobacter fuscus MCy9118 Cystomanamide 
Cystobacter violaceus Cb vi35 Vioprolide 
Haliangium ochraceum MNa9133 BSYN63 
Myxococcus xanthus DK897 BSYN406 
Myxococcus xanthus MCy9151 BSYN52, BSYN50 
Myxococcus xanthus MxA47 BSYN301, BSYN292 
Myxococcus fulvus MCy11108 BSYN151, BSYN152 
Myxococcus fulvus MCy9270 BSYN518, BSYN490 
Myxococcus stipitatus MCy9235 BSYN78, BSYN76, BSYN546, BSYN71, 
BSYN544, BSYN75, BSYN547 
Pyxodicoccus unclassified MCy9557 BSYN161, BSYN159, BSYN165, 
BSYN169, BSYN158, BSYN160 
Sorangium cellulosum Soce26 BSYN229, BSYN244 
Sorangium cellulosum Soce38 BSYN749 
Sorangium cellulosum Soce56 BSYN258 
Sorangium cellulosum Soce307 BSYN715 
Sorangium cellulosum Soce836 BSYN283, BSYN266 
Sorangium cellulosum Soce1128 BSYN206, BSYN194 
Sorangium cellulosum MSr11115  BSYN191 
Sorangium cellulosum SoceGT47 BSYN140 
Stigmatella erecta Pde77 BSYN554 
unclassified unclassified Ar3548 BSYN350, BSYN363, BSYN356, 
BSYN354, BSYN342, BSYN332, 
BSYN344 
unclassified unclassified Ccc127 BSYN404, BSYN397 
* only cystomanamide, corramycin (unpublished) and vioprolide (unpublished) 
gene clusters have been characterized; other gene clusters are given in original 
name. 
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3.7 The unsolved mystery − mechanism of Maz formation  
As vioprolide A and C are not produced in C. violaceus Cb vi35 and 
heterologous hosts, it is not yet certain which protein catalyzed the formation of 
Maz. The next step is to find appropriate media and cultivating conditions to 
activate the production of vioprolide A and C. Only when vioprolide A and C 
are produced, could we find the precursor of Maz by isotope feeding. There are 
two reasons to consider methionine as the precursor of the 4-methylazetidine 
carboxylic acid (Maz). On the one hand, methyl groups are transferred from 
methionine by S-adenosylmethionine (SAM) dependent methyltransferase in 
numerous methylation reactions in the secondary metabolites biosynthesis [63]. 
The vio gene cluster does contain an S-adenosylmethionine (SAM) dependent 
methyltransferase (ORF6). On the other hand, the formation of azetidine 
carboxylic acid (AZE) has been shown to be relevant to the methionine cycle in 
gramineous plants [64–68]. Considering that some SAM-dependent 
methyltransferases could rearrange the carbon skeleton [63], the amino acids 
with similar carbon skeletion with Maz, such as proline and valine, could also be 
counted as candidate precursors. If the production of vioprolide A and C could 
be activated in C. violaceus Cb vi35, it is possible to find the Maz catalyzing 
protein by quatitative transcriptomics or quatitative proteomics strategy. We 
could cultivate C. violaceus Cb vi35 in different conditions and analyze the 
change of transcriptome or proteome. 
 
3.8 Perspectives 
The elucidation of vioprolide biosynthetic mechanism deepened our 
knowledge about natural product biosynthesis and established a platform to 
produce vioprolide analogues. The improvement of production yield sets the 
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stage for pharmacological and toxicological research as well as industrial 
production of vioprolides.  
The research on the MOA of vioprolides would be a prospective direction of 
this project. If the cytotoxic and antifungal mechanisms of vioprolides could be 
elucidated in the future, more derivatives may be rationally generated to increase 
the specificity and activity to the target. High toxicity of vioprolides A-C on 
both healthy and carcinoma cells hindered their development to anti-cancer 
agents. It is thus necessary to reduce their toxic effects on healthy cells but 
retain the cytotoxicity towards cancer cells by structural modifications. 
Conjugating vioprolides with tumor specific monoclonal antibodies could also 
be an option to reduce their cytotoxicity on healthy cells. In addition, vioprolide 
D is a promising antifungal candidate. The research on its MOA is urgent 
because of the limited number of antifungal pharmaceuticals on the market and 
the severe situation of antifungal resistance. Moreover, vioprolides have 
potential to treat diseases susceptible to interferon α and β (US Patent: US 
2010/0028298 A1), the immune-enhancing mechanism of vioprolides will also 
be of future interest. The investigations on these topics will proceed faster in the 
future due to the increased and stable availability of vioprolides. 
The elucidation of Maz forming mechanism would be valuable for both 
fundamental research and industrial application. The Maz catalytic protein could 
be an element for combinatorial biosynthesis. Novel structures may be generated 
by introducing Maz catalytic protein into other L-Pro incorporating 
megasynthetases (e.g. myxochromide NRPS). Although we were not able to 
elucidate the mechanism for Maz formation in this study, activating the 
production of vioprolide A and C in C. violaceus Cb vi35 should lead to the 
identification of the precursor and the protein involve in Maz formation. As Maz 
is not produced in heterologous systems, it is possible to generate a mutant 
producing only vioprolide D by deleting the vioZ gene, which may elevate the 
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production yield of vioprolide D and could save considerable effort for 
downstream purifications. 
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